ACS Publications. Most Trusted. Most Cited. Most Read
Quick View

OR SEARCH CITATIONS

My Activity
Publications
CONTENT TYPES

Figure 1Loading Img
Download Hi-Res ImageDownload to MS-PowerPointCite This:Nano Lett. 2020, 20, 7, 5570-5574
RETURN TO ISSUEPREVLetterNEXT

Cellular Nanosponges Inhibit SARS-CoV-2 Infectivity

  • Qiangzhe Zhang
    Qiangzhe Zhang
    Department of NanoEngineering, Chemical Engineering Program and Moores Cancer Center, University of California San Diego, La Jolla, California 92093, United States
    More by Qiangzhe Zhang
  • , 
  • Anna Honko
    Anna Honko
    Department of Microbiology and National Emerging Infectious Diseases Laboratories, Boston University School of Medicine, Boston, Massachusetts 02118, United States
    More by Anna Honko
  • , 
  • Jiarong Zhou
    Jiarong Zhou
    Department of NanoEngineering, Chemical Engineering Program and Moores Cancer Center, University of California San Diego, La Jolla, California 92093, United States
    More by Jiarong Zhou
  • , 
  • Hua Gong
    Hua Gong
    Department of NanoEngineering, Chemical Engineering Program and Moores Cancer Center, University of California San Diego, La Jolla, California 92093, United States
    More by Hua Gong
  • , 
  • Sierra N. Downs
    Sierra N. Downs
    Department of Microbiology and National Emerging Infectious Diseases Laboratories, Boston University School of Medicine, Boston, Massachusetts 02118, United States
    More by Sierra N. Downs
  • , 
  • Jhonatan Henao Vasquez
    Jhonatan Henao Vasquez
    Department of Microbiology and National Emerging Infectious Diseases Laboratories, Boston University School of Medicine, Boston, Massachusetts 02118, United States
    More by Jhonatan Henao Vasquez
  • , 
  • Ronnie H. Fang
    Ronnie H. Fang
    Department of NanoEngineering, Chemical Engineering Program and Moores Cancer Center, University of California San Diego, La Jolla, California 92093, United States
    More by Ronnie H. Fang
  • , 
  • Weiwei Gao
    Weiwei Gao
    Department of NanoEngineering, Chemical Engineering Program and Moores Cancer Center, University of California San Diego, La Jolla, California 92093, United States
    More by Weiwei Gao
  • , 
  • Anthony Griffiths*
    Anthony Griffiths
    Department of Microbiology and National Emerging Infectious Diseases Laboratories, Boston University School of Medicine, Boston, Massachusetts 02118, United States
    *Email: [email protected]
    More by Anthony Griffiths
  • , and 
  • Liangfang Zhang*
    Liangfang Zhang
    Department of NanoEngineering, Chemical Engineering Program and Moores Cancer Center, University of California San Diego, La Jolla, California 92093, United States
    *Email: [email protected]
    More by Liangfang Zhang
    Orcidhttp://orcid.org/0000-0003-0637-0654
Cite this: Nano Lett. 2020, 20, 7, 5570–5574
Publication Date (Web):June 17, 2020
https://doi.org/10.1021/acs.nanolett.0c02278

Copyright © 2020 American Chemical Society. This publication is licensed under these Terms of Use.

Request reuse permissions
  • Open Access

Article Views

30873

Altmetric

-

Citations

256
LEARN ABOUT THESE METRICS
PDF (3 MB)
Get e-Alerts
Supporting Info (1)»
SUBJECTS:

Abstract

High Resolution Image
Download MS PowerPoint Slide

We report cellular nanosponges as an effective medical countermeasure to the SARS-CoV-2 virus. Two types of cellular nanosponges are made of the plasma membranes derived from human lung epithelial type II cells or human macrophages. These nanosponges display the same protein receptors, both identified and unidentified, required by SARS-CoV-2 for cellular entry. It is shown that, following incubation with the nanosponges, SARS-CoV-2 is neutralized and unable to infect cells. Crucially, the nanosponge platform is agnostic to viral mutations and potentially viral species, as well. As long as the target of the virus remains the identified host cell, the nanosponges will be able to neutralize the virus.

KEYWORDS:

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused an outbreak of coronavirus disease (COVID-19), and the pandemic has unfolded into a severe global public health crisis. (1,2) Remdesivir is currently the most advanced antiviral drug for COVID-19 treatment, which received an emergency-use authorization in the United States for patients with severe disease, but the mortality benefit is unproven. (3) The search for new drugs requires a clear understanding of the underlying molecular mechanisms of viral infection, which is a particular challenge with emerging viruses such as SARS-CoV-2. (4,5) Moreover, antiviral medicine often targets a specific viral species that cannot be deployed across different species or families of viruses and may be rendered ineffective as the virus accumulates mutations and escapes treatments. (6) Therefore, an effective therapeutic agent to inhibit SARS-CoV-2 infectivity, as well as its potential mutated species, would be a significant game changer in the battle against this public health crisis.

Early understanding of the clinical manifestation of COVID-19 is severe viral pneumonia. Emerging data are clear that SARS-CoV-2 elicits significant damage on other organ systems either directly or indirectly through downstream immunological effects. (7) Up to 75% of COVID-19 patients present with some renal involvement, with a significant portion of patients developing acute kidney injury. (8) Acute respiratory distress syndrome (ARDS) is a common and deadly manifestation of COVID-19 and is associated with prolonged intubation and high mortality. (9) Typically, COVID-19 patients initially present mild symptoms, yet a subset of patients rapidly develop complications such as ARDS and multiorgan failure and ultimately death. The rapid clinical deterioration is thought to be closely related to the cytokine storm. (10) Recently, coagulopathy has been described as a critical morbidity in COVID-19 patients and is associated with worse outcomes. (11) All of these clinical complications speak to the complexity of this disease and that the consequence of immune response to the viral infection may be the main driver of morbidity and mortality of COVID-19.

A novel approach to drug development is to place the focus on the affected host cells instead of targeting the causative agent. Inspired by the fact that the infectivity of SARS-CoV-2 relies on its binding with the protein receptors, either known or unknown, on the target cells, we create cellular nanosponges as a medical countermeasure to the coronavirus. These nanosponges are made of human-cell-derived membranes, which are sourced from cells that are naturally targeted by SARS-CoV-2 (Figure 1A). The nanosponges display the same receptors that the viruses depend on for cellular entry. We hypothesize that, upon binding with nanosponges, the coronaviruses are unable to infect their usual cellular targets. SARS-CoV-2 uses angiotensin-converting enzyme 2 (ACE2) and CD147 expressed on the host cells, such as human alveolar epithelial type II cells, as receptors for cellular entry. (12) Human macrophages both express CD147 and have been reported to play a significant role in the infection by frequent interactions with virus-targeted cells through chemokines and phagocytosis signaling pathways. (13)

Figure 1

Figure 1. Fabrication and characterization of cellular nanosponges. (A) Schematic mechanism of cellular nanosponges inhibiting SARS-CoV-2 infectivity. The nanosponges were constructed by wrapping polymeric nanoparticle (NP) cores with natural cell membranes from target cells such as lung epithelial cells and macrophages (MΦs). The resulting nanosponges (denoted “Epithelial-NS” and “MΦ-NS”, respectively) inherit the surface antigen profiles of the source cells and serve as decoys to bind with SARS-CoV-2. Such binding interaction blocks viral entry and inhibits viral infectivity. (B) Dynamic light scattering measurements of hydrodynamic size (diameter, nm) and surface zeta-potential (ζ, mV) of polymeric NP cores before and after coating with cell membranes (n = 3; mean + standard deviation). (C) Selective protein bands of cell lysate, cell membrane vesicles, and cellular nanosponges resolved with Western blotting analysis. (D) Comparison of the fluorescence intensity measured from cellular nanosponges (100 μL, 0.5 mg/mL membrane protein concentration) or source cells (100 μL, approximately 2.5 × 106 cells) containing equal amounts of membrane content and stained with fluorescently labeled antibodies (n = 3; mean + standard deviation; n.s.: not significant; statistical analysis was performed with paired two-tailed t-test). (E) Stability of cellular nanosponges in 1× phosphate-buffered saline determined by monitoring particle size (diameter, nm) over a span of 7 days (n = 3; mean ± standard deviation).

High Resolution Image
Download MS PowerPoint Slide

Based upon the current knowledge of SARS-CoV-2, we fabricated two types of cellular nanosponges, human lung epithelial type II cell nanosponge (denoted “Epithelial-NS”) and human macrophage nanosponge (denoted “MΦ-NS”). The resulting cellular nanosponges were thoroughly characterized for their physicochemical and biological properties, followed by in vivo evaluation of their safety in the lungs. Then, these samples were independently tested in a biosafety level 4 (BSL-4) laboratory for inhibitory effects on human SARS-CoV-2 virus and demonstrated clear antiviral efficacy in vitro.

To prepare cellular nanosponges, cell membranes of human lung epithelial cells and macrophages were derived with a differential centrifugation method and verified for purity. The membranes were then coated onto polymeric nanoparticle cores made from poly(lactic-co-glycolic acid) (PLGA) with a sonication method to form Epithelial-NS and MΦ-NS, respectively. When examined with dynamic light scattering, both Epithelial-NS and MΦ-NS showed hydrodynamic diameters larger than that of the uncoated PLGA cores (Figure 1B). The surface zeta-potential of the nanosponges was less negative than that of the PLGA cores but comparable to that of the source cells (Table S1). These changes are consistent with the addition of a bilayer cell membrane. Cell membrane coating allows nanosponges to inherit the viral receptors related to coronavirus entry into the host cells. For verification, Western blot analysis showed the presence of viral receptors such as ACE2, transmembrane serine protease 2 (TMPRSS2), and dipeptidyl peptidase IV (DPP4) on the Epithelial-NS, and ACE2, C-type lectin domain family 10 (CLEC10), and CD147 on the MΦ-NS (Figure 1C). (12,13) The results also showed that the nanosponge preparation facilitated membrane protein retention and enrichment on the nanosponges, without contamination from intracellular proteins (Figure S1). For viral neutralization, right-side-out membrane orientation, driven by the asymmetric repulsion between the cores and the extracellular membrane versus the intracellular membrane, is essential. (14) To examine the membrane sidedness, we stained cellular nanosponges and their source cells containing equal amounts of membrane content using fluorescently labeled antibodies against select membrane antigens. After the removal of free antibodies, cellular nanosponge samples showed fluorescence intensities comparable with those of the cell samples (Figure 1D). This indicates that the nanosponges adopted a right-side-out membrane orientation because inside-out membrane coating would reduce antibody staining. (15) The membrane coating also provided cellular nanosponges with extended colloidal stability in 1× phosphate-buffered saline (Figure 1E).

After confirming the successful fabrication of Epithelial-NS and MΦ-NS, we sought to evaluate their acute toxicity after in vivo administration in mice. Given that our intended use is the deployment of cellular nanosponges for the treatment of coronavirus infections that predominantly affect the respiratory tract, (9) we elected to study the intratracheal route of administration using the highest feasible dose of Epithelial-NS or MΦ-NS (300 μg, based on membrane protein, in a suspension of 20 μL). Histopathological analysis of lung tissue 3 days after nanosponge administration revealed that immune infiltration was similar to baseline levels, and there was no evidence of lesion formation or tissue damage (Figure 2A). Furthermore, we examined multiple blood parameters, including a comprehensive serum chemistry panel and blood cell counts, 3 days after nanosponge administration (Figure 2B,C). All of the blood markers that were studied, in addition to red blood cells, platelets, and white blood cell counts, were consistent with baseline levels, confirming the short-term safety of the cellular nanosponges.

Figure 2

Figure 2. In vivo safety of cellular nanosponges. (A) Hematoxylin and eosin (H&E) staining of representative lung sections taken 3 days after intratracheal administration of the cellular nanosponges (scale bar: 250 μm). (B) Comprehensive serum chemistry panel performed 3 days after intratracheal administration of the cellular nanosponges (n = 3; mean + standard deviation). ALB, albumin; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AMY, amylase; BUN, urea nitrogen; CA, calcium; CRE, creatinine; GLOB, globulin (calculated); GLU, glucose; K+, potassium; NA+, sodium; PHOS, phosphorus; TBIL, total bilirubin; TP, total protein. (C) Blood cell counts 3 days after intratracheal administration of cellular nanosponges (n = 3; mean + standard deviation).

High Resolution Image
Download MS PowerPoint Slide

We next evaluated the neutralization of infectivity by authentic SARS-CoV-2 with a plaque reduction neutralization test. In the study, a low passage sample of SARS-CoV-2 (USA-WA1/2020, World Reference Center for Emerging Viruses and Arboviruses) (16) was amplified in Vero E6 cells to make a working stock of the virus. Vero E6 cells were seeded at 8 × 105 cells per well in 6-well plates the day prior to the experiment. Serial quarter-log dilutions of the nanosponges were mixed with 200 plaque-forming units (PFU) of SARS-CoV-2. The mixture was incubated at 37 °C for 1 h and then added to the cell monolayers followed by an additional 1 h of incubation. Mock-infected and diluent-only infected wells served as negative and positive controls, respectively. Monolayers were overlaid and incubated for 2 days followed by viral plaque enumeration. Following the incubation, cultures without adding Epithelial-NS showed a viral count comparable to that in the negative control, confirming viral entry and infection of the host cells. Inhibition of the infectivity increased as the concentration of Epithelial-NS increased, suggesting a dose-dependent neutralization effect (Figure 3A). Based on the results, a half-maximal inhibitory concentration (IC50) value of 827.1 μg/mL for Epithelial-NS was obtained. In parallel, a similar dose-dependent inhibition of the viral infectivity was observed with MΦ-NS (Figure 3B). In this case, an IC50 value of 882.7 μg/mL was obtained. These results indicate that the Epithelial-NS and MΦ-NS have comparable ability to inhibit viral infectivity of SARS-CoV-2. To further verify that the inhibition was indeed due to epithelial cell or macrophage membrane coating, control nanosponges made from membranes of red blood cells (denoted “RBC-NS”) were also tested in parallel for viral inhibition but were not effective in neutralizing SARS-CoV-2 infection of Vero E6 cells (Figure 3C).

Figure 3

Figure 3. Cellular nanosponges neutralize SARS-CoV-2 infectivity. The neutralization against SARS-CoV-2 infection by (A) Epithelial-NS, (B) MΦ-NS, and (C) nanosponges made from red blood cell membranes (RBC-NS, used as a control) was tested using live SARS-CoV-2 viruses on Vero E6 cells. The IC50 values for Epithelial-NS and MΦ-NS were found to be 827.1 and 882.7 μg/mL (membrane protein concentration), respectively. In all data sets, n = 3. Data are presented as mean + standard deviation. Horizontal dashed lines mark the zero levels. IC50 values were derived from the variable slope model using Graphpad Prism 8.

High Resolution Image
Download MS PowerPoint Slide

As a novel virus causing the current global pandemic, new information regarding SARS-CoV-2 is emerging on a daily basis. Since the first case that was reported at the end of 2019, it has been shown that the virus is mutating at a rapid rate. (17) This rapid rate of mutation will pose a major challenge to the development of therapeutics and preventive measures. (18) Both Epithelial-NS and MΦ-NS demonstrated the ability to neutralize SARS-CoV-2 in a concentration-dependent manner. The nanosponge platform offers a unique benefit over other therapies currently in development for COVID-19 in that the nanosponges are mutation and potentially virus agnostic. In principle, as long as the target of the virus remains the identified host cell, the nanosponges will be able to neutralize the infection, providing a broad-acting countermeasure resistant to mutations and protection against this and other emerging coronaviruses. The utility of the cellular nanosponges for the treatment of SARS-CoV-2 infection requires further validation in appropriate animal models, which is currently underway, and this will pave the way for human clinical trials in the future. Moreover, optimization of the lead formulation may further improve the antiviral efficacy of these nanosponges.

For the treatment of COVID-19, MΦ-NS may have some significant advantages over Epithelial-NS. The clinical manifestation of COVID-19 is partially driven by direct viral damage but primarily by the immune response to the infection. Previous studies on SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV) demonstrated that macrophages play a significant role in the pathogenesis of those infections. Emerging data from SARS-CoV-2 also paint a similar picture, where macrophages play a central role either through direct viral entry via CD147 or downstream hyperinflammatory response to SARS-CoV-2. (19) Our previous work has demonstrated that MΦ-NS has a broad-spectrum neutralization capability, including against bacterial toxins and inflammatory cytokines. (20) Specific to COVID-19, MΦ-NS can neutralize the viral activity not only early on to reduce the viral load in the body but also even late in disease, and it will be able to address the fulminant inflammation associated with COVID-19. Given the central role that macrophages play in the immune system, the application of MΦ-NS extends beyond infections such as SARS-CoV-2 and may have significant roles in treating inflammatory diseases such as sepsis and other autoimmune diseases.

Supporting Information

ARTICLE SECTIONS
Jump To

The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acs.nanolett.0c02278.

  • Materials and methods, Figure S1, and Table S1 (PDF)

Terms & Conditions

Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: http://pubs.acs.org/page/copyright/permissions.html.

Author Information

ARTICLE SECTIONS
Jump To
  • Corresponding Authors
    • Anthony Griffiths - Department of Microbiology and National Emerging Infectious Diseases Laboratories, Boston University School of Medicine, Boston, Massachusetts 02118, United States;  Email: [email protected]
    • Liangfang Zhang - Department of NanoEngineering, Chemical Engineering Program and Moores Cancer Center, University of California San Diego, La Jolla, California 92093, United States;  Orcidhttp://orcid.org/0000-0003-0637-0654;  Email: [email protected]
  • Authors
    • Qiangzhe Zhang - Department of NanoEngineering, Chemical Engineering Program and Moores Cancer Center, University of California San Diego, La Jolla, California 92093, United States
    • Anna Honko - Department of Microbiology and National Emerging Infectious Diseases Laboratories, Boston University School of Medicine, Boston, Massachusetts 02118, United States
    • Jiarong Zhou - Department of NanoEngineering, Chemical Engineering Program and Moores Cancer Center, University of California San Diego, La Jolla, California 92093, United States
    • Hua Gong - Department of NanoEngineering, Chemical Engineering Program and Moores Cancer Center, University of California San Diego, La Jolla, California 92093, United States
    • Sierra N. Downs - Department of Microbiology and National Emerging Infectious Diseases Laboratories, Boston University School of Medicine, Boston, Massachusetts 02118, United States
    • Jhonatan Henao Vasquez - Department of Microbiology and National Emerging Infectious Diseases Laboratories, Boston University School of Medicine, Boston, Massachusetts 02118, United States
    • Ronnie H. Fang - Department of NanoEngineering, Chemical Engineering Program and Moores Cancer Center, University of California San Diego, La Jolla, California 92093, United States
    • Weiwei Gao - Department of NanoEngineering, Chemical Engineering Program and Moores Cancer Center, University of California San Diego, La Jolla, California 92093, United States
  • Notes
    The authors declare the following competing financial interest(s): L.Z. discloses financial interest in Cellics Therapeutics.

Acknowledgments

ARTICLE SECTIONS
Jump To

This work is supported by the Defense Threat Reduction Agency Joint Science and Technology Office for Chemical and Biological Defense under Grant No. HDTRA1-18-1-0014. The following reagent was obtained through BEI Resources, NIAID, NIH: VERO C1008 (E6), Kidney (African green monkey), Working Cell Bank, NR-596. The SARS-CoV-2 starting material was provided by the World Reference Center for Emerging Viruses and Arboviruses (WRCEVA), with Natalie Thornburg ([email protected]) as the CDC Principal Investigator. Avicel RC-591 was kindly provided by DuPont Nutrition & Health.

References

ARTICLE SECTIONS
Jump To

This article references 20 other publications.

  1. 1
    Munster, V. J.; Koopmans, M.; van Doremalen, N.; van Riel, D.; de Wit, E. A novel coronavirus emerging in china - key questions for impact assessment. N. Engl. J. Med. 2020, 382, 692– 694,  DOI: 10.1056/NEJMp2000929
    Google Scholar
    1
    A novel coronavirus emerging in China - key questions for impact assessment
    Munster, Vincent J.; Koopmans, Marion; van Doremalen, Neeltje; van Riel, Debby; de Wit, Emmie
    New England Journal of Medicine (2020), 382 (8), 692-694CODEN: NEJMAG; ISSN:1533-4406. (Massachusetts Medical Society)
    A review. After initial reports of a SARS-like virus emerging in Wuhan, it appears that SARS-CoV-2 (2019-nCoV) may be less pathogenic than MERS-CoV and SARS-CoV. However, the virus's emergence raises an important question: What is the role of overall pathogenicity in our ability to contain emerging viruses, prevent large-scale spread, and prevent them from causing a pandemic or becoming endemic in the human population. Important questions regarding any emerging virus concern the shape of the disease pyramid, the proportion of infected people who develop disease, and the proportion of those who seek health care; these three points inform the classic surveillance pyramid. Emerging coronaviruses raise an addnl. question of how widespread the virus is in its reservoir. Epidemiol. information on the pathogenicity and transmissibility of this virus obtained by means of mol. detection and serosurveillance is needed to fill in the details in the surveillance pyramid and guide the response to this outbreak. Moreover, the propensity of novel coronaviruses to spread in health care centers indicates a need for peripheral health care facilities to be on standby to identify potential cases as well. In addn., increased preparedness is needed at animal markets and other animal facilities, while the possible source of this emerging virus is being investigated.
    >> More from SciFinder ®
    https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjslGltrk%253D&md5=6af431f001d8a97fa0fea77441998489
  2. 2
    Wu, D.; Wu, T. T.; Liu, Q.; Yang, Z. C. The SARS-CoV-2 outbreak: What we know. Int. J. Infect. Dis. 2020, 94, 44– 48,  DOI: 10.1016/j.ijid.2020.03.004
    Google Scholar
    2
    The SARS-CoV-2 outbreak: What we know
    Wu, Di; Wu, Tiantian; Liu, Qun; Yang, Zhicong
    International Journal of Infectious Diseases (2020), 94 (), 44-48CODEN: IJIDF3; ISSN:1201-9712. (Elsevier Ltd.)
    A review. There is a current worldwide outbreak of the novel coronavirus Covid-19 (coronavirus disease 2019; the pathogen called SARS-CoV-2; previously 2019-nCoV), which originated from Wuhan in China and has now spread to 6 continents including 66 countries, as of 24:00 on March 2, 2020. Governments are under increased pressure to stop the outbreak from spiraling into a global health emergency. At this stage, preparedness, transparency, and sharing of information are crucial to risk assessments and beginning outbreak control activities. This information should include reports from outbreak site and from labs. supporting the investigation. This paper aggregates and consolidates the epidemiol., clin. manifestations, diagnosis, treatments and preventions of this new type of coronavirus.
    >> More from SciFinder ®
    https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXntlensbY%253D&md5=b0d3662114f26b797adf9beaa28952d7
  3. 3
    Wang, Y.; Zhang, D.; Du, G.; Du, R.; Zhao, J.; Jin, Y.; Fu, S.; Gao, L.; Cheng, Z.; Lu, Q.; Hu, Y.; Luo, G.; Wang, K.; Lu, Y.; Li, H.; Wang, S.; Ruan, S.; Yang, C.; Mei, C.; Wang, Y.; Ding, D.; Wu, F.; Tang, X.; Ye, X.; Ye, Y.; Liu, B.; Yang, J.; Yin, W.; Wang, A.; Fan, G.; Zhou, F.; Liu, Z.; Gu, X.; Xu, J.; Shang, L.; Zhang, Y.; Cao, L.; Guo, T.; Wan, Y.; Qin, H.; Jiang, Y.; Jaki, T.; Hayden, F. G.; Horby, P. W.; Cao, B.; Wang, C. Remdesivir in adults with severe COVID-19: A randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2020, 395, 1569– 1578,  DOI: 10.1016/S0140-6736(20)31022-9
    Google Scholar
    3
    Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial
    Wang, Yeming; Zhang, Dingyu; Du, Guanhua; Du, Ronghui; Zhao, Jianping; Jin, Yang; Fu, Shouzhi; Gao, Ling; Cheng, Zhenshun; Lu, Qiaofa; Hu, Yi; Luo, Guangwei; Wang, Ke; Lu, Yang; Li, Huadong; Wang, Shuzhen; Ruan, Shunan; Yang, Chengqing; Mei, Chunlin; Wang, Yi; Ding, Dan; Wu, Feng; Tang, Xin; Ye, Xianzhi; Ye, Yingchun; Liu, Bing; Yang, Jie; Yin, Wen; Wang, Aili; Fan, Guohui; Zhou, Fei; Liu, Zhibo; Gu, Xiaoying; Xu, Jiuyang; Shang, Lianhan; Zhang, Yi; Cao, Lianjun; Guo, Tingting; Wan, Yan; Qin, Hong; Jiang, Yushen; Jaki, Thomas; Hayden, Frederick G.; Horby, Peter W.; Cao, Bin; Wang, Chen
    Lancet (2020), 395 (10236), 1569-1578CODEN: LANCAO; ISSN:0140-6736. (Elsevier Ltd.)
    No specific antiviral drug has been proven effective for treatment of patients with severe coronavirus disease 2019 (COVID-19). Remdesivir (GS-5734), a nucleoside analog prodrug, has inhibitory effects on pathogenic animal and human coronaviruses, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in vitro, and inhibits Middle East respiratory syndrome coronavirus, SARS-CoV-1, and SARS-CoV-2 replication in animal models. We did a randomized, double-blind, placebo-controlled, multicenter trial at ten hospitals in Hubei, China. Eligible patients were adults (aged ≥18 years) admitted to hospital with lab.-confirmed SARS-CoV-2 infection, with an interval from symptom onset to enrollment of 12 days or less, oxygen satn. of 94% or less on room air or a ratio of arterial oxygen partial pressure to fractional inspired oxygen of 300 mm Hg or less, and radiol. confirmed pneumonia. Patients were randomly assigned in a 2:1 ratio to i.v. remdesivir (200 mg on day 1 followed by 100 mg on days 2-10 in single daily infusions) or the same vol. of placebo infusions for 10 days. Patients were permitted concomitant use of lopinavir-ritonavir, interferons, and corticosteroids. The primary endpoint was time to clin. improvement up to day 28, defined as the time (in days) from randomization to the point of a decline of two levels on a six-point ordinal scale of clin. status (from 1=discharged to 6=death) or discharged alive from hospital, whichever came first. Primary anal. was done in the intention-to-treat (ITT) population and safety anal. was done in all patients who started their assigned treatment. This trial is registered with ClinicalTrials.gov, NCT04257656. Between Feb 6, 2020, and March 12, 2020, 237 patients were enrolled and randomly assigned to a treatment group (158 to remdesivir and 79 to placebo); one patient in the placebo group who withdrew after randomization was not included in the ITT population. Remdesivir use was not assocd. with a difference in time to clin. improvement (hazard ratio 1·23 [95% CI 0·87-1·75]). Although not statistically significant, patients receiving remdesivir had a numerically faster time to clin. improvement than those receiving placebo among patients with symptom duration of 10 days or less (hazard ratio 1·52 [0·95-2·43]). Adverse events were reported in 102 (66%) of 155 remdesivir recipients vs. 50 (64%) of 78 placebo recipients. Remdesivir was stopped early because of adverse events in 18 (12%) patients vs. four (5%) patients who stopped placebo early. In this study of adult patients admitted to hospital for severe COVID-19, remdesivir was not assocd. with statistically significant clin. benefits. However, the numerical redn. in time to clin. improvement in those treated earlier requires confirmation in larger studies. Chinese Academy of Medical Sciences Emergency Project of COVID-19, National Key Research and Development Program of China, the Beijing Science and Technol. Project.
    >> More from SciFinder ®
    https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXosVWlurc%253D&md5=160af7f665ed7fe089e9c07b3bec1acd
  4. 4
    Bekerman, E.; Einav, S. Combating emerging viral threats. Science 2015, 348, 282– 283,  DOI: 10.1126/science.aaa3778
    Google Scholar
    4
    Combating emerging viral threats
    Bekerman, Elena; Einav, Shirit
    Science (Washington, DC, United States) (2015), 348 (6232), 282-283CODEN: SCIEAS; ISSN:0036-8075. (American Association for the Advancement of Science)
    There is no expanded citation for this reference.
    >> More from SciFinder ®
    https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXosVKjt7Y%253D&md5=1cf54cc0a7db0925573f96ed72c27c11
  5. 5
    Catanzaro, M.; Fagiani, F.; Racchi, M.; Corsini, E.; Govoni, S.; Lanni, C. Immune response in COVID-19: Addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2. Signal Transduct. Target. Ther. 2020, 5, 84,  DOI: 10.1038/s41392-020-0191-1
    Google Scholar
    5
    Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2
    Catanzaro Michele; Fagiani Francesca; Racchi Marco; Govoni Stefano; Lanni Cristina; Fagiani Francesca; Corsini Emanuela
    Signal transduction and targeted therapy (2020), 5 (1), 84 ISSN:.
    To date, no vaccines or effective drugs have been approved to prevent or treat COVID-19 and the current standard care relies on supportive treatments. Therefore, based on the fast and global spread of the virus, urgent investigations are warranted in order to develop preventive and therapeutic drugs. In this regard, treatments addressing the immunopathology of SARS-CoV-2 infection have become a major focus. Notably, while a rapid and well-coordinated immune response represents the first line of defense against viral infection, excessive inflammatory innate response and impaired adaptive host immune defense may lead to tissue damage both at the site of virus entry and at systemic level. Several studies highlight relevant changes occurring both in innate and adaptive immune system in COVID-19 patients. In particular, the massive cytokine and chemokine release, the so-called "cytokine storm", clearly reflects a widespread uncontrolled dysregulation of the host immune defense. Although the prospective of counteracting cytokine storm is compelling, a major limitation relies on the limited understanding of the immune signaling pathways triggered by SARS-CoV-2 infection. The identification of signaling pathways altered during viral infections may help to unravel the most relevant molecular cascades implicated in biological processes mediating viral infections and to unveil key molecular players that may be targeted. Thus, given the key role of the immune system in COVID-19, a deeper understanding of the mechanism behind the immune dysregulation might give us clues for the clinical management of the severe cases and for preventing the transition from mild to severe stages.
    >> More from SciFinder ®
    https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB38rivVOmuw%253D%253D&md5=3fb8e4f85321d6225c5c4922661eab10
  6. 6
    Zumla, A.; Chan, J. F. W.; Azhar, E. I.; Hui, D. S. C.; Yuen, K. Y. Coronaviruses - drug discovery and therapeutic options. Nat. Rev. Drug Discovery 2016, 15, 327– 347,  DOI: 10.1038/nrd.2015.37
    Google Scholar
    6
    Coronaviruses - drug discovery and therapeutic options
    Zumla, Alimuddin; Chan, Jasper F. W.; Azhar, Esam I.; Hui, David S. C.; Yuen, Kwok-Yung
    Nature Reviews Drug Discovery (2016), 15 (5), 327-347CODEN: NRDDAG; ISSN:1474-1776. (Nature Publishing Group)
    A review. In humans, infections with the human coronavirus (HCoV) strains HCoV-229E, HCoV-OC43, HCoV-NL63 and HCoV-HKU1 usually result in mild, self-limiting upper respiratory tract infections, such as the common cold. By contrast, the CoVs responsible for severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), which were discovered in Hong Kong, China, in 2003, and in Saudi Arabia in 2012, resp., have received global attention over the past 12 years owing to their ability to cause community and health-care-assocd. outbreaks of severe infections in human populations. These two viruses pose major challenges to clin. management because there are no specific antiviral drugs available. In this Review, we summarize the epidemiol., virol., clin. features and current treatment strategies of SARS and MERS, and discuss the discovery and development of new virus-based and host-based therapeutic options for CoV infections.
    >> More from SciFinder ®
    https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XisVyru70%253D&md5=437159fc2f3885395268bd6d97e34a0b
  7. 7
    Tay, M. Z.; Poh, C. M.; Renia, L.; MacAry, P. A.; Ng, L. F. P. The trinity of COVID-19: Immunity, inflammation and intervention. Nat. Rev. Immunol. 2020, 20, 363– 374,  DOI: 10.1038/s41577-020-0311-8
    Google Scholar
    7
    The trinity of COVID-19: immunity, inflammation and intervention
    Tay, Matthew Zirui; Poh, Chek Meng; Renia, Laurent; MacAry, Paul A.; Ng, Lisa F. P.
    Nature Reviews Immunology (2020), 20 (6), 363-374CODEN: NRIABX; ISSN:1474-1733. (Nature Research)
    A review. A review. Abstr.: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the ongoing coronavirus disease 2019 (COVID-19) pandemic. Alongside investigations into the virol. of SARS-CoV-2, understanding the fundamental physiol. and immunol. processes underlying the clin. manifestations of COVID-19 is vital for the identification and rational design of effective therapies. Here, we provide an overview of the pathophysiol. of SARS-CoV-2 infection. We describe the interaction of SARS-CoV-2 with the immune system and the subsequent contribution of dysfunctional immune responses to disease progression. From nascent reports describing SARS-CoV-2, we make inferences on the basis of the parallel pathophysiol. and immunol. features of the other human coronaviruses targeting the lower respiratory tract - severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV). Finally, we highlight the implications of these approaches for potential therapeutic interventions that target viral infection and/or immunoregulation.
    >> More from SciFinder ®
    https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXot1aksbw%253D&md5=3513ef4a1bfc1dd043269044484bdb44
  8. 8
    Pei, G.; Zhang, Z.; Peng, J.; Liu, L.; Zhang, C.; Yu, C.; Ma, Z.; Huang, Y.; Liu, W.; Yao, Y.; Zeng, R.; Xu, G. Renal involvement and early prognosis in patients with COVID-19 pneumonia. J. Am. Soc. Nephrol. 2020, 31, 1157– 1165,  DOI: 10.1681/ASN.2020030276
    Google Scholar
    8
    Renal involvement and early prognosis in patients with COVID-19 pneumonia
    Pei, Guangchang; Zhang, Zhiguo; Peng, Jing; Liu, Liu; Zhang, Chunxiu; Yu, Chong; Ma, Zufu; Huang, Yi; Liu, Wei; Yao, Ying; Zeng, Rui; Xu, Gang
    Journal of the American Society of Nephrology (2020), 31 (6), 1157-1165CODEN: JASNEU; ISSN:1046-6673. (American Society of Nephrology)
    Background: Some patients with COVID-19 pneumonia also present with kidney injury, and autopsy findings of patients who died from the illness sometimes show renal damage. However, little is known about the clin. characteristics of kidney-related complications, including hematuria, proteinuria, and AKI. Methods: In this retrospective, single-center study in China, we analyzed data from electronic medical records of 333 hospitalized patients with COVID-19 pneumonia, including information about clin., lab., radiol., and other characteristics, as well as information about renal outcomes. Results: We found that 251 of the 333 patients (75.4%) had abnormal urine dipstick tests or AKI. Of 198 patients with renal involvement for the median duration of 12 days, 118 (59.6%) experienced remission of pneumonia during this period, and 111 of 162 (68.5%) patients experienced remission of proteinuria. Among 35 patients who developed AKI (with AKI identified by criteria expanded somewhat beyond the 2012 Kidney Disease: Improving Global Outcomes definition), 16 (45.7%) experienced complete recovery of kidney function. We suspect that most AKI cases were intrinsic AKI. Patients with renal involvement had higher overall mortality compared with those without renal involvement (28 of 251 [11.2%] vs. one of 82 [1.2%], resp.). Stepwise multivariate binary logistic regression analyses showed that severity of pneumonia was the risk factor most commonly assocd. with lower odds of proteinuric or hematuric remission and recovery from AKI. Conclusions: Renal abnormalities occurred in the majority of patients with COVID-19 pneumonia. Although proteinuria, hematuria, and AKI often resolved in such patients within 3 wk after the onset of symptoms, renal complications in COVID-19 were assocd. with higher mortality.
    >> More from SciFinder ®
    https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitFCqsrjI&md5=13a3b6835152e54faeb73a31819c9917
  9. 9
    Zangrillo, A.; Beretta, L.; Scandroglio, A. M.; Monti, G.; Fominskiy, E.; Colombo, S.; Morselli, F.; Belletti, A.; Silvani, P.; Crivellari, M.; Monaco, F.; Azzolini, M. L.; Reineke, R.; Nardelli, P.; Sartorelli, M.; Votta, C. D.; Ruggeri, A.; Ciceri, F.; Cobelli, F. D.; Tresoldi, M.-n.; Dagna, L.; Rovere-Querini, P.; Neto, A. S.; Bellomo, R.; Landon, G. Characteristics, treatment, outcomes and cause of death of invasively ventilated patients with COVID-19 ARDS in Milan, Italy. Crit. Care Resusc. 2020; published online ahead of print.
    Google Scholar
    There is no corresponding record for this reference.
  10. 10
    Ye, Q.; Wang, B.; Mao, J. The pathogenesis and treatment of the ‘cytokine storm’ in COVID-19. J. Infect. 2020, 80, 607– 613,  DOI: 10.1016/j.jinf.2020.03.037
    Google Scholar
    10
    The pathogenesis and treatment of the 'Cytokine Storm' in COVID-19
    Ye, Qing; Wang, Bili; Mao, Jianhua
    Journal of Infection (2020), 80 (6), 607-613CODEN: JINFD2; ISSN:0163-4453. (Elsevier B.V.)
    A review. Cytokine storm is a general term applied to maladaptive cytokine release in response to infection and other stimuli. The pathogenesis is complex but includes loss of regulatory control of proinflammatory cytokine prodn., both at local and systemic levels. The disease progresses rapidly, and the mortality is high. Some evidence shows that, during the coronavirus disease 2019 (COVID-19) epidemic, severe deterioration in some patients has been closely assocd. with dysregulated and excessive cytokine release. This article reviews what we know of the mechanism and treatment strategies of the COVID-19 virus-induced inflammatory storm in an attempt to provide some background to inform future guidance for clin. treatment.
    >> More from SciFinder ®
    https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtVantL%252FP&md5=21ad8db56c54cab280db18e344231dab
  11. 11
    Connors, J. M.; Levy, J. H. COVID-19 and its implications for thrombosis and anticoagulation. Blood 2020, 135, 2033– 2040,  DOI: 10.1182/blood.2020006000
    Google Scholar
    11
    COVID-19 and its implications for thrombosis and anticoagulation
    Connors, Jean M.; Levy, Jerrold H.
    Blood (2020), 135 (23), 2033-2040CODEN: BLOOAW; ISSN:1528-0020. (American Society of Hematology)
    Severe acute respiratory syndrome coronavirus 2, coronavirus disease 2019 (COVID-19)-induced infection can be assocd. with a coagulopathy, findings consistent with infection-induced inflammatory changes as obsd. in patients with disseminated intravascular coagulopathy (DIC). The lack of prior immunity to COVID-19 has resulted in large nos. of infected patients across the globe and uncertainty regarding management of the complications that arise in the course of this viral illness. The lungs are the target organ for COVID-19; patients develop acute lung injury that can progress to respiratory failure, although multiorgan failure can also occur. The initial coagulopathy of COVID-19 presents with prominent elevation of D-dimer and fibrin/fibrinogen-degrdn. products, whereas abnormalities in prothrombin time, partial thromboplastin time, and platelet counts are relatively uncommon in initial presentations. Coagulation test screening, including the measurement of D-dimer and fibrinogen levels, is suggested. COVID-19-assocd. coagulopathy should be managed as it would be for any critically ill patient, following the established practice of using thromboembolic prophylaxis for critically ill hospitalized patients, and std. supportive care measures for those with sepsis-induced coagulopathy or DIC. Although D-dimer, sepsis physiol., and consumptive coagulopathy are indicators of mortality, current data do not suggest the use of full-intensity anticoagulation doses unless otherwise clin. indicated. Even though there is an assocd. coagulopathy with COVID-19, bleeding manifestations, even in those with DIC, have not been reported. If bleeding does occur, std. guidelines for the management of DIC and bleeding should be followed.
    >> More from SciFinder ®
    https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtlSjs7nJ&md5=850a0e9f6688ac64f69dd016403ae9dc
  12. 12
    Yan, R. H.; Zhang, Y. Y.; Li, Y. N.; Xia, L.; Guo, Y. Y.; Zhou, Q. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science 2020, 367, 1444– 1448,  DOI: 10.1126/science.abb2762
    Google Scholar
    12
    Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2
    Yan, Renhong; Zhang, Yuanyuan; Li, Yaning; Xia, Lu; Guo, Yingying; Zhou, Qiang
    Science (Washington, DC, United States) (2020), 367 (6485), 1444-1448CODEN: SCIEAS; ISSN:1095-9203. (American Association for the Advancement of Science)
    Angiotensin-converting enzyme 2 (ACE2) is the cellular receptor for severe acute respiratory syndrome coronavirus (SARS-CoV) and the new coronavirus (SARS-CoV-2) that is causing the serious coronavirus disease 2019 (COVID-19) epidemic. Here, we present cryo-electron microscopy structures of full-length human ACE2 in the presence of the neutral amino acid transporter B0AT1 with or without the receptor binding domain (RBD) of the surface spike glycoprotein (S protein) of SARS-CoV-2, both at an overall resoln. of 2.9 angstroms, with a local resoln. of 3.5 angstroms at the ACE2-RBD interface. The ACE2-B0AT1 complex is assembled as a dimer of heterodimers, with the collectrin-like domain of ACE2 mediating homodimerization. The RBD is recognized by the extracellular peptidase domain of ACE2 mainly through polar residues. These findings provide important insights into the mol. basis for coronavirus recognition and infection.
    >> More from SciFinder ®
    https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXlslymsLo%253D&md5=ff4dfdfc646ea878cfb325019160e94a
  13. 13
    Qi, F.; Qian, S.; Zhang, S.; Zhang, Z. Single cell rna sequencing of 13 human tissues identify cell types and receptors of human coronaviruses. Biochem. Biophys. Res. Commun. 2020, 526, 135– 140,  DOI: 10.1016/j.bbrc.2020.03.044
    Google Scholar
    13
    Single cell RNA sequencing of 13 human tissues identify cell types and receptors of human coronaviruses
    Qi, Furong; Qian, Shen; Zhang, Shuye; Zhang, Zheng
    Biochemical and Biophysical Research Communications (2020), 526 (1), 135-140CODEN: BBRCA9; ISSN:0006-291X. (Elsevier B.V.)
    The new coronavirus (SARS-CoV-2) outbreak from Dec. 2019 in Wuhan, Hubei, China, has been declared a global public health emergency. Angiotensin I converting enzyme 2 (ACE2), is the host receptor by SARS-CoV-2 to infect human cells. Although ACE2 is reported to be expressed in lung, liver, stomach, ileum, kidney and colon, its expressing levels are rather low, esp. in the lung. SARS-CoV-2 may use co-receptors/auxiliary proteins as ACE2 partner to facilitate the virus entry. To identify the potential candidates, we explored the single cell gene expression atlas including 119 cell types of 13 human tissues and analyzed the single cell co-expression spectrum of 51 reported RNA virus receptors and 400 other membrane proteins. Consistent with other recent reports, we confirmed that ACE2 was mainly expressed in lung AT2, liver cholangiocyte, colon colonocytes, esophagus keratinocytes, ileum ECs, rectum ECs, stomach epithelial cells, and kidney proximal tubules. Intriguingly, we found that the candidate co-receptors, manifesting the most similar expression patterns with ACE2 across 13 human tissues, are all peptidases, including ANPEP, DPP4 and ENPEP. Among them, ANPEP and DPP4 are the known receptors for human CoVs, suggesting ENPEP as another potential receptor for human CoVs. We also conducted "CellPhoneDB" anal. to understand the cell crosstalk between CoV-targets and their surrounding cells across different tissues. We found that macrophages frequently communicate with the CoVs targets through chemokine and phagocytosis signaling, highlighting the importance of tissue macrophages in immune defense and immune pathogenesis.
    >> More from SciFinder ®
    https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXlt1Wrt78%253D&md5=7f484d8f3654456f18e7a7ca9c5dd80a
  14. 14
    Luk, B. T.; Hu, C. M. J.; Fang, R. N. H.; Dehaini, D.; Carpenter, C.; Gao, W.; Zhang, L. Interfacial interactions between natural RBC membranes and synthetic polymeric nanoparticles. Nanoscale 2014, 6, 2730– 2737,  DOI: 10.1039/C3NR06371B
    Google Scholar
    14
    Interfacial interactions between natural RBC membranes and synthetic polymeric nanoparticles
    Luk, Brian T.; Jack Hu, Che-Ming; Fang, Ronnie H.; Dehaini, Diana; Carpenter, Cody; Gao, Weiwei; Zhang, Liangfang
    Nanoscale (2014), 6 (5), 2730-2737CODEN: NANOHL; ISSN:2040-3372. (Royal Society of Chemistry)
    The unique structural features and stealth properties of a recently developed red blood cell membrane-cloaked nanoparticle (RBC-NP) platform raise curiosity over the interfacial interactions between natural cellular membranes and polymeric nanoparticle substrates. Herein, several interfacial aspects of the RBC-NPs are examd., including completeness of membrane coverage, membrane sidedness upon coating, and the effects of polymeric particles' surface charge and surface curvature on the membrane cloaking process. The study shows that RBC membranes completely cover neg. charged polymeric nanoparticles in a right-side-out manner and enhance the particles' colloidal stability. The membrane cloaking process is applicable to particle substrates with a diam. ranging from 65 to 340 nm. Addnl., the study reveals that both surface glycans on RBC membranes and the substrate properties play a significant role in driving and directing the membrane-particle assembly. These findings further the understanding of the dynamics between cellular membranes and nanoscale substrates and provide valuable information toward future development and characterization of cellular membrane-cloaked nanodevices.
    >> More from SciFinder ®
    https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXisVahtbo%253D&md5=c27d7e12b232e07e284e60572bf1f104
  15. 15
    Wei, X. L.; Zhang, G.; Ran, D. N.; Krishnan, N.; Fang, R. H.; Gao, W.; Spector, S. A.; Zhang, L. T-cell-mimicking nanoparticles can neutralize HIV infectivity. Adv. Mater. 2018, 30, 1802233,  DOI: 10.1002/adma.201802233
    Google Scholar
    There is no corresponding record for this reference.
  16. 16
    Harcourt, J.; Tamin, A.; Lu, X.; Kamili, S.; Sakthivel, S. K.; Murray, J.; Queen, K.; Tao, Y.; Paden, C. R.; Zhang, J.; Li, Y.; Uehara, A.; Wang, H.; Goldsmith, C.; Bullock, H. A.; Wang, L.; Whitaker, B.; Lynch, B.; Gautam, R.; Schindewolf, C.; Lokugamage, K. G.; Scharton, D.; Plante, J. A.; Mirchandani, D.; Widen, S. G.; Narayanan, K.; Makino, S.; Ksiazek, T. G.; Plante, K. S.; Weaver, S. C.; Lindstrom, S.; Tong, S.; Menachery, V. D.; Thornburg, N. J. Severe acute respiratory syndrome coronavirus 2 from patient with 2019 novel coronavirus disease, United States. Emerging Infect. Dis. 2020, 26, 1266– 1273,  DOI: 10.3201/eid2606.200516
    Google Scholar
    16
    Severe acute respiratory syndrome coronavirus 2 from patient with coronavirus disease, United States
    Harcourt, Jennifer; Tamin, Azaibi; Lu, Xiaoyan; Kamili, Shifaq; Sakthivel, Senthil K.; Murray, Janna; Queen, Krista; Tao, Ying; Paden, Clinton R.; Zhang, Jing; Li, Yan; Uehara, Anna; Wang, Haibin; Goldsmith, Cynthia; Bullock, Hannah A.; Wang, Lijuan; Whitaker, Brett; Lynch, Brian; Gautam, Rashi; Schindewolf, Craig; Lokugamage, Kumari G.; Scharton, Dionna; Plante, Jessica A.; Mirchandani, Divya; Widen, Steven G.; Narayanan, Krishna; Makino, Shinji; Ksiazek, Thomas G.; Plante, Kenneth S.; Weaver, Scott C.; Lindstrom, Stephen; Tong, Suxiang; Menachery, Vineet D.; Thornburg, Natalie J.
    Emerging Infectious Diseases (2020), 26 (6), 1266-1273CODEN: EIDIFA; ISSN:1080-6059. (Centers for Disease Control and Prevention)
    The etiol. agent of an outbreak of pneumonia in Wuhan, China, was identified as severe acute respiratory syndrome coronavirus 2 in Jan. 2020. A patient in the United States was given a diagnosis of infection with this virus by the state of Washington and the US Centers for Disease Control and Prevention on Jan. 20, 2020. We isolated virus from nasopharyngeal and oropharyngeal specimens from this patient and characterized the viral sequence, replication properties, and cell culture tropism. The virus replicates to high titer in Vero-CCL81 cells and Vero E6 cells in the absence of trypsin. We also deposited the virus into 2 virus repositories, making it broadly available to the public health and research communities. We hope that open access to this reagent will expedite development of medical countermeasures.
    >> More from SciFinder ®
    https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtlarurvN&md5=89075c420b0de7e286500c984a4e5a42
  17. 17
    Cyranoski, D. Profile of a killer: The complex biology powering the coronavirus pandemic. Nature 2020, 581, 22– 26,  DOI: 10.1038/d41586-020-01315-7
    Google Scholar
    17
    Profile of a killer: the complex biology powering the coronavirus pandemic
    Cyranoski, David
    Nature (London, United Kingdom) (2020), 581 (7806), 22-26CODEN: NATUAS; ISSN:0028-0836. (Nature Research)
    Scientists are piecing together how SARS-CoV-2 operates, where it came from and what it might do next - but pressing questions remain about the source of COVID-19.
    >> More from SciFinder ®
    https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXosV2jurc%253D&md5=826e66de35a020886c414db4dbdd0ed0
  18. 18
    Becerra-Flores, M.; Cardozo, T. SARS-CoV-2 viral spike G614 mutation exhibits higher case fatality rate. Int. J. Clin. Pract. 2020,  DOI: 10.1111/ijcp.13525
    Google Scholar
    There is no corresponding record for this reference.
  19. 19
    Merad, M.; Martin, J. C. Pathological inflammation in patients with COVID-19: A key role for monocytes and macrophages. Nat. Rev. Immunol. 2020, 20, 355– 362,  DOI: 10.1038/s41577-020-0331-4
    Google Scholar
    19
    Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages
    Merad, Miriam; Martin, Jerome C.
    Nature Reviews Immunology (2020), 20 (6), 355-362CODEN: NRIABX; ISSN:1474-1733. (Nature Research)
    A review. Abstr.: The COVID-19 pandemic caused by infection with SARS-CoV-2 has led to more than 200,000 deaths worldwide. Several studies have now established that the hyperinflammatory response induced by SARS-CoV-2 is a major cause of disease severity and death in infected patients. Macrophages are a population of innate immune cells that sense and respond to microbial threats by producing inflammatory mols. that eliminate pathogens and promote tissue repair. However, a dysregulated macrophage response can be damaging to the host, as is seen in the macrophage activation syndrome induced by severe infections, including in infections with the related virus SARS-CoV. Here we describe the potentially pathol. roles of macrophages during SARS-CoV-2 infection and discuss ongoing and prospective therapeutic strategies to modulate macrophage activation in patients with COVID-19.
    >> More from SciFinder ®
    https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXoslOqt7s%253D&md5=d38b037fed1fcc469e6c8caa23777fc7
  20. 20
    Thamphiwatana, S.; Angsantikul, P.; Escajadillo, T.; Zhang, Q. Z.; Olson, J.; Luk, B. T.; Zhang, S.; Fang, R. H.; Gao, W.; Nizet, V.; Zhang, L. Macrophage-like nanoparticles concurrently absorbing endotoxins and proinflammatory cytokines for sepsis management. Proc. Natl. Acad. Sci. U. S. A. 2017, 114, 11488– 11493,  DOI: 10.1073/pnas.1714267114
    Google Scholar
    20
    Macrophage-like nanoparticles concurrently absorbing endotoxins and proinflammatory cytokines for sepsis management
    Thamphiwatana, Soracha; Angsantikul, Pavimol; Escajadillo, Tamara; Zhang, Qiangzhe; Olson, Joshua; Luk, Brian T.; Zhang, Sophia; Fang, Ronnie H.; Gao, Weiwei; Nizet, Victor; Zhang, Liangfang
    Proceedings of the National Academy of Sciences of the United States of America (2017), 114 (43), 11488-11493CODEN: PNASA6; ISSN:0027-8424. (National Academy of Sciences)
    Sepsis, resulting from uncontrolled inflammatory responses to bacterial infections, continues to cause high morbidity and mortality worldwide. Currently, effective sepsis treatments are lacking in the clinic, and care remains primarily supportive. Here we report the development of macrophage biomimetic nanoparticles for the management of sepsis. The nanoparticles, made by wrapping polymeric cores with cell membrane derived from macrophages, possess an antigenic exterior the same as the source cells. By acting as macrophage decoys, these nanoparticles bind and neutralize endotoxins that would otherwise trigger immune activation. In addn., these macrophage-like nanoparticles sequester proinflammatory cytokines and inhibit their ability to potentiate the sepsis cascade. In a mouse Escherichia coli bacteremia model, treatment with macrophage mimicking nanoparticles, termed MΦ-NPs, reduced proinflammatory cytokine levels, inhibited bacterial dissemination, and ultimately conferred a significant survival advantage to infected mice. Employing MΦ-NPs as a biomimetic detoxification strategy shows promise for improving patient outcomes, potentially shifting the current paradigm of sepsis management.
    >> More from SciFinder ®
    https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1aisr7J&md5=7d85b146ca874333f82bed02c57bdabd

Cited By

ARTICLE SECTIONS
Jump To

This article is cited by 256 publications.

  1. Sukanya Patra, Divya Pareek, Prem Shankar Gupta, Kirti Wasnik, Gurmeet Singh, Desh Deepak Yadav, Yitzhak Mastai, Pradip Paik. Progress in Treatment and Diagnostics of Infectious Disease with Polymers. ACS Infectious Diseases 2024, 10 (2) , 287-316. https://doi.org/10.1021/acsinfecdis.3c00528
  2. Jingzhe Wang, Tonggong Liu, Siyao Gu, Hui-hui Yang, Weidong Xie, Cheng Gao, Dayong Gu. Cytoplasm Hydrogelation-Mediated Cardiomyocyte Sponge Alleviated Coxsackievirus B3 Infection. Nano Letters 2023, 23 (19) , 8881-8890. https://doi.org/10.1021/acs.nanolett.3c01983
  3. Yaou Duan, Edward Zhang, Ronnie H. Fang, Weiwei Gao, Liangfang Zhang. Capsulated Cellular Nanosponges for the Treatment of Experimental Inflammatory Bowel Disease. ACS Nano 2023, 17 (16) , 15893-15904. https://doi.org/10.1021/acsnano.3c03959
  4. Alap Ali Zahid, Aishik Chakraborty, Wei Luo, Ali Coyle, Arghya Paul. Tailoring the Inherent Properties of Biobased Nanoparticles for Nanomedicine. ACS Biomaterials Science & Engineering 2023, 9 (7) , 3972-3986. https://doi.org/10.1021/acsbiomaterials.3c00364
  5. Yuzhi Ouyang, Yancao Chen, Jinhui Shang, Shijie Sun, Xiangbin Wang, Shuangyan Huan, Bin Xiong, Xiao-Bing Zhang. Virus-like Plasmonic Nanoprobes for Quick Analysis of Antiviral Efficacy and Mutation-Induced Drug Resistance. Analytical Chemistry 2023, 95 (11) , 5009-5017. https://doi.org/10.1021/acs.analchem.2c05464
  6. Maya Holay, Nishta Krishnan, Jiarong Zhou, Yaou Duan, Zhongyuan Guo, Weiwei Gao, Ronnie H. Fang, Liangfang Zhang. Single Low-Dose Nanovaccine for Long-Term Protection against Anthrax Toxins. Nano Letters 2022, 22 (23) , 9672-9678. https://doi.org/10.1021/acs.nanolett.2c03881
  7. Dan Wang, Xiangzhao Ai, Yaou Duan, Nianfei Xian, Ronnie H. Fang, Weiwei Gao, Liangfang Zhang. Neuronal Cellular Nanosponges for Effective Detoxification of Neurotoxins. ACS Nano 2022, 16 (11) , 19145-19154. https://doi.org/10.1021/acsnano.2c08319
  8. Kazushige Yokoyama . Investigation of Protein-Protein Interactions Utilizing a Nano-Gold Colloid Surface Plasmon Resonance: Application to SARS CoV-2 Spike Protein Coated Gold Colloids. , 145-164. https://doi.org/10.1021/bk-2022-1429.ch009
  9. Adrian Najer, Joshua Blight, Catherine B. Ducker, Matteo Gasbarri, Jonathan C. Brown, Junyi Che, Håkon Høgset, Catherine Saunders, Miina Ojansivu, Zixuan Lu, Yiyang Lin, Jonathan Yeow, Omar Rifaie-Graham, Michael Potter, Renée Tonkin, Jelle Penders, James J. Doutch, Athina Georgiadou, Hanna M. G. Barriga, Margaret N. Holme, Aubrey J. Cunnington, Laurence Bugeon, Margaret J. Dallman, Wendy S. Barclay, Francesco Stellacci, Jake Baum, Molly M. Stevens. Potent Virustatic Polymer–Lipid Nanomimics Block Viral Entry and Inhibit Malaria Parasites In Vivo. ACS Central Science 2022, 8 (9) , 1238-1257. https://doi.org/10.1021/acscentsci.1c01368
  10. Meiling Lian, Yuqing Shi, Liuxing Chen, Yongji Qin, Wei Zhang, Jingbo Zhao, Da Chen. Cell Membrane and V2C MXene-Based Electrochemical Immunosensor with Enhanced Antifouling Capability for Detection of CD44. ACS Sensors 2022, 7 (9) , 2701-2709. https://doi.org/10.1021/acssensors.2c01215
  11. Lizhong Sun, Meng Li, Jiaojiao Yang, Jiyao Li. Cell Membrane-Coated Nanoparticles for Management of Infectious Diseases: A Review. Industrial & Engineering Chemistry Research 2022, 61 (35) , 12867-12883. https://doi.org/10.1021/acs.iecr.2c01587
  12. Xiaoyi Ma, Shiyu Guo, Shuangrong Ruan, Yao Liu, Jie Zang, Yushan Yang, Haiqing Dong, Yan Li, Tianbin Ren, Maomao An, Yongyong Li. HACE2-Exosome-Based Nano-Bait for Concurrent SARS-CoV-2 Trapping and Antioxidant Therapy. ACS Applied Materials & Interfaces 2022, 14 (4) , 4882-4891. https://doi.org/10.1021/acsami.1c19541
  13. Teri W. Odom (Editor-in-Chief). Nano Letters in the Time of COVID-19. Nano Letters 2022, 22 (1) , 1-2. https://doi.org/10.1021/acs.nanolett.1c04813
  14. Vaishali Chugh, K. Vijaya Krishna, Abhay Pandit. Cell Membrane-Coated Mimics: A Methodological Approach for Fabrication, Characterization for Therapeutic Applications, and Challenges for Clinical Translation. ACS Nano 2021, 15 (11) , 17080-17123. https://doi.org/10.1021/acsnano.1c03800
  15. Xiangzhao Ai, Dan Wang, Anna Honko, Yaou Duan, Igor Gavrish, Ronnie H. Fang, Anthony Griffiths, Weiwei Gao, Liangfang Zhang. Surface Glycan Modification of Cellular Nanosponges to Promote SARS-CoV-2 Inhibition. Journal of the American Chemical Society 2021, 143 (42) , 17615-17621. https://doi.org/10.1021/jacs.1c07798
  16. Erin M. Duffy, Ed T. Buurman, Su L. Chiang, Nadia R. Cohen, Maria Uria-Nickelsen, Richard A. Alm. The CARB-X Portfolio of Nontraditional Antibacterial Products. ACS Infectious Diseases 2021, 7 (8) , 2043-2049. https://doi.org/10.1021/acsinfecdis.1c00331
  17. Yunan Zhao, Aixue Li, Liangdi Jiang, Yongwei Gu, Jiyong Liu. Hybrid Membrane-Coated Biomimetic Nanoparticles (HM@BNPs): A Multifunctional Nanomaterial for Biomedical Applications. Biomacromolecules 2021, 22 (8) , 3149-3167. https://doi.org/10.1021/acs.biomac.1c00440
  18. Manjing Li, Zhaojian Xu, Lu Zhang, Mingyue Cui, Manhui Zhu, Yang Guo, Rong Sun, Junfei Han, E Song, Yao He, Yuanyuan Su. Targeted Noninvasive Treatment of Choroidal Neovascularization by Hybrid Cell-Membrane-Cloaked Biomimetic Nanoparticles. ACS Nano 2021, 15 (6) , 9808-9819. https://doi.org/10.1021/acsnano.1c00680
  19. Maya Holay, Zhongyuan Guo, Jessica Pihl, Jiyoung Heo, Joon Ho Park, Ronnie H. Fang, Liangfang Zhang. Bacteria-Inspired Nanomedicine. ACS Applied Bio Materials 2021, 4 (5) , 3830-3848. https://doi.org/10.1021/acsabm.0c01072
  20. Bader M. Jarai, Zachary Stillman, Kartik Bomb, April M. Kloxin, Catherine A. Fromen. Biomaterials-Based Opportunities to Engineer the Pulmonary Host Immune Response in COVID-19. ACS Biomaterials Science & Engineering 2021, 7 (5) , 1742-1764. https://doi.org/10.1021/acsbiomaterials.0c01287
  21. Cheng Wang, Shaobo Wang, Yin Chen, Jianqi Zhao, Songling Han, Gaomei Zhao, Jing Kang, Yong Liu, Liting Wang, Xiaoyang Wang, Yang Xu, Song Wang, Yi Huang, Junping Wang, Jinghong Zhao. Membrane Nanoparticles Derived from ACE2-Rich Cells Block SARS-CoV-2 Infection. ACS Nano 2021, 15 (4) , 6340-6351. https://doi.org/10.1021/acsnano.0c06836
  22. Ajeet Kumar Kaushik, Jaspreet Singh Dhau, Hardik Gohel, Yogendra Kumar Mishra, Babak Kateb, Nam-Young Kim, Dharendra Yogi Goswami. Electrochemical SARS-CoV-2 Sensing at Point-of-Care and Artificial Intelligence for Intelligent COVID-19 Management. ACS Applied Bio Materials 2020, 3 (11) , 7306-7325. https://doi.org/10.1021/acsabm.0c01004
  23. Jack C. Tang, Raviraj Vankayala, Jenny T. Mac, Bahman Anvari. RBC-Derived Optical Nanoparticles Remain Stable After a Freeze–Thaw Cycle. Langmuir 2020, 36 (34) , 10003-10011. https://doi.org/10.1021/acs.langmuir.0c00637
  24. Qin Qin, Xinyi Jiang, Liyun Huo, Jiaqiang Qian, Hongyuan Yu, Haixia Zhu, Wenhao Du, Yuhui Cao, Xing Zhang, Qiang Huang. Computational design and engineering of self-assembling multivalent microproteins with therapeutic potential against SARS-CoV-2. Journal of Nanobiotechnology 2024, 22 (1) https://doi.org/10.1186/s12951-024-02329-3
  25. Jia-You Fang, Kuo-Yen Huang, Tong-Hong Wang, Zih-Chan Lin, Chin-Chuan Chen, Sui-Yuan Chang, En-Li Chen, Tai-Ling Chao, Shuenn-Chen Yang, Pan-Chyr Yang, Chi-Yuan Chen. Development of nanoparticles incorporated with quercetin and ACE2-membrane as a novel therapy for COVID-19. Journal of Nanobiotechnology 2024, 22 (1) https://doi.org/10.1186/s12951-024-02435-2
  26. Mohsen Ghiasi, Peyman Kheirandish Zarandi, Abdolreza Dayani, Ali Salimi, Ehsan Shokri. Potential therapeutic effects and nano-based delivery systems of mesenchymal stem cells and their isolated exosomes to alleviate acute respiratory distress syndrome caused by COVID-19. Regenerative Therapy 2024, 27 , 319-328. https://doi.org/10.1016/j.reth.2024.03.015
  27. Samane Teymouri, Maryam Pourhajibagher, Abbas Bahador. Exosomes: Friends or Foes in Microbial Infections?. Infectious Disorders - Drug Targets 2024, 24 (5) https://doi.org/10.2174/0118715265264388231128045954
  28. Saba Asif Qureshi, Km Rafiya, Sakshi Awasthi, Abhishek Jain, Arif Nadaf, Nazeer Hasan, Prashant Kesharwani, Farhan Jalees Ahmad. Biomembrane camouflaged nanoparticles: A paradigm shifts in targeted drug delivery system. Colloids and Surfaces B: Biointerfaces 2024, 238 , 113893. https://doi.org/10.1016/j.colsurfb.2024.113893
  29. Lei Sun, Dan Wang, Kailin Feng, Jiayuan Alex Zhang, Weiwei Gao, Liangfang Zhang. Cell membrane-coated nanoparticles for targeting carcinogenic bacteria. Advanced Drug Delivery Reviews 2024, 209 , 115320. https://doi.org/10.1016/j.addr.2024.115320
  30. Rui Gao, Peihong Lin, Zhengyu Fang, Wenjing Yang, Wenyan Gao, Fangqian Wang, Xuwang Pan, Wenying Yu. Cell-derived biomimetic nanoparticles for the targeted therapy of ALI/ARDS. Drug Delivery and Translational Research 2024, 14 (6) , 1432-1457. https://doi.org/10.1007/s13346-023-01494-6
  31. Sundus Qureshi, Seyed Ebrahim Alavi, Yousuf Mohammed. Microsponges: Development, Characterization, and Key Physicochemical Properties. ASSAY and Drug Development Technologies 2024, 8 https://doi.org/10.1089/adt.2023.052
  32. Shatha A Albalawi, Raneem A Albalawi, Amaal A Albalawi, Raghad F. Alanazi, Raghad M. Almahlawi, Basma S. Alhwity, Bashayer D. Alatawi, Nehal Elsherbiny, Saleh F. Alqifari, Mohamed S. Abdel-Maksoud. The Possible Mechanisms of Cu and Zn in the Treatment and Prevention of HIV and COVID-19 Viral Infection. Biological Trace Element Research 2024, 202 (4) , 1524-1538. https://doi.org/10.1007/s12011-023-03788-9
  33. Yu Zheng, Yuke Li, Mao Li, Rujing Wang, Yuhong Jiang, Mengnan Zhao, Jun Lu, Rui Li, Xiaofang Li, Sanjun Shi. COVID‐19 cooling: Nanostrategies targeting cytokine storm for controlling severe and critical symptoms. Medicinal Research Reviews 2024, 44 (2) , 738-811. https://doi.org/10.1002/med.21997
  34. Changjiang Gu, Xiangwu Geng, Yicheng Wu, Yuya Dai, Junkai Zeng, Zhenqiang wang, Huapan Fang, Yanqing Sun, Xiongsheng Chen. Engineered Macrophage Membrane‐Coated Nanoparticles with Enhanced CCR2 Expression Promote Spinal Cord Injury Repair by Suppressing Neuroinflammation and Neuronal death. Small 2024, 20 (10) https://doi.org/10.1002/smll.202305659
  35. Yafang Xiao, Yuanyu Huang, Maobin Xie, Minghui Yang, Ying Tao, Lu Liu, Jiasheng Wu, Guoxi Xie, Jinbao Liu, Tao Xu, Weisheng Guo, Xing-Jie Liang. Immunoregulatory nanomedicine for respiratory infections. Nature Reviews Bioengineering 2024, 2 (3) , 244-259. https://doi.org/10.1038/s44222-023-00131-8
  36. Laura Libnan Haidar, Marcela Bilek, Behnam Akhavan. Surface Bio‐engineered Polymeric Nanoparticles. Small 2024, 721 https://doi.org/10.1002/smll.202310876
  37. Sheng Chen, Enen Chen, Xiaoling Guan, Junfang Li, Aiping Qin, Chen Wang, Xihua Fu, Chen Huang, Jianhao Li, Yukuan Tang, Minyan Wei, Lingmin Zhang, Jianfen Su. Magnetically controlled nanorobots induced oriented and rapid clearance of the cytokine storm for acute lung injury therapy. Colloids and Surfaces B: Biointerfaces 2024, 234 , 113731. https://doi.org/10.1016/j.colsurfb.2023.113731
  38. Bedanta Bhattacharjee, Damanbhalang Rynjah, Abdul Baquee Ahmed, Arzoo Newar, Sindhuja Sengupta, Sanheeta Chakrabarty, Ram Kumar Sahu, Jiyauddin Khan. Overview of diagnostic tools and nano-based therapy of SARS-CoV-2 infection. Chemical Papers 2024, 78 (4) , 2123-2154. https://doi.org/10.1007/s11696-023-03271-8
  39. Yiyan Yu, Yifei Peng, Wei‐Ting Shen, Zhidong Zhou, Mingxuan Kai, Weiwei Gao, Liangfang Zhang. Hybrid Cell Membrane‐Coated Nanoparticles for Biomedical Applications. Small Structures 2024, 49 https://doi.org/10.1002/sstr.202300473
  40. Xi Wang, Yixuan Li, Xueyu Pu, Guiquan Liu, Honglin Qin, Weimin Wan, Yuying Wang, Yan Zhu, Jian Yang. Macrophage-related therapeutic strategies: Regulation of phenotypic switching and construction of drug delivery systems. Pharmacological Research 2024, 199 , 107022. https://doi.org/10.1016/j.phrs.2023.107022
  41. Han Zhang, Yanbin Liu, Zhuang Liu. Nanomedicine approaches against SARS-CoV-2 and variants. Journal of Controlled Release 2024, 365 , 101-111. https://doi.org/10.1016/j.jconrel.2023.11.004
  42. Mo Li, Qiushi Guo, Chongli Zhong, Ziyan Zhang. Multifunctional cell membranes-based nano-carriers for targeted therapies: a review of recent trends and future perspective. Drug Delivery 2023, 30 (1) https://doi.org/10.1080/10717544.2023.2288797
  43. Jinglin Xu, Dongxue Li, Lin Kang, Tingting Liu, Jing Huang, Jiaxin Li, Jing Lv, Jing Wang, Shan Gao, Yanwei Li, Bing Yuan, Baohua Zhao, Jinglin Wang, Wenwen Xin. Systematic evaluation of membrane-camouflaged nanoparticles in neutralizing Clostridium perfringens ε-toxin. Journal of Nanobiotechnology 2023, 21 (1) https://doi.org/10.1186/s12951-023-01852-z
  44. Akriti Rai, Kamal Shah, Rajiv Sharma, Hitesh Kumar Dewangan. A Comprehensive Review on COVID-19: Emphasis on Current Vaccination and Nanotechnology Aspects. Recent Patents on Nanotechnology 2023, 17 (4) , 359-377. https://doi.org/10.2174/1872210516666220819104853
  45. Xiaoming Hu, Shuang Wang, Shaotong Fu, Meng Qin, Chengliang Lyu, Zhaowen Ding, Yan Wang, Yishu Wang, Dongshu Wang, Li Zhu, Tao Jiang, Jing Sun, Hui Ding, Jie Wu, Lingqian Chang, Yimin Cui, Xiaocong Pang, Youchun Wang, Weijin Huang, Peidong Yang, Limin Wang, Guanghui Ma, Wei Wei. Intranasal mask for protecting the respiratory tract against viral aerosols. Nature Communications 2023, 14 (1) https://doi.org/10.1038/s41467-023-44134-w
  46. Yaou Duan, Jiarong Zhou, Zhidong Zhou, Edward Zhang, Yiyan Yu, Nishta Krishnan, Daniela Silva‐Ayala, Ronnie H. Fang, Anthony Griffiths, Weiwei Gao, Liangfang Zhang. Extending the In Vivo Residence Time of Macrophage Membrane‐Coated Nanoparticles through Genetic Modification. Small 2023, 19 (52) https://doi.org/10.1002/smll.202305551
  47. Ying Qu, Bingyang Chu, Jianan Li, Hanzhi Deng, Ting Niu, Zhiyong Qian. Macrophage‐Biomimetic Nanoplatform‐Based Therapy for Inflammation‐Associated Diseases. Small Methods 2023, 1 https://doi.org/10.1002/smtd.202301178
  48. Sushant Sunder, Kriti Bhandari, Shruti Sounkaria, Manjari Vyas, Bhupendra Pratap Singh, Prakash Chandra. Antibiotics and nano-antibiotics in treatment of lung infection: In management of COVID-19. Microbial Pathogenesis 2023, 184 , 106356. https://doi.org/10.1016/j.micpath.2023.106356
  49. Xiangzhao Ai, Dan Wang, Ilkoo Noh, Yaou Duan, Zhidong Zhou, Nilesh Mukundan, Ronnie H. Fang, Weiwei Gao, Liangfang Zhang. Glycan-modified cellular nanosponges for enhanced neutralization of botulinum toxin. Biomaterials 2023, 302 , 122330. https://doi.org/10.1016/j.biomaterials.2023.122330
  50. Fatemeh Araste, Astrid Diana Bakker, Behrouz Zandieh-Doulabi. Potential and risks of nanotechnology applications in COVID-19-related strategies for pandemic control. Journal of Nanoparticle Research 2023, 25 (11) https://doi.org/10.1007/s11051-023-05867-3
  51. Zhaokui Jin, Qi Gao, Keke Wu, Jiang Ouyang, Weisheng Guo, Xing-Jie Liang. Harnessing inhaled nanoparticles to overcome the pulmonary barrier for respiratory disease therapy. Advanced Drug Delivery Reviews 2023, 368 , 115111. https://doi.org/10.1016/j.addr.2023.115111
  52. Manorama Dey, Garvita Dhanawat, Divya Gupta, Ayush Goel, Krishnan H Harshan, Nagma Parveen. Giant Plasma Membrane Vesicles as Cellular‐Mimics for Probing SARS‐CoV‐2 Binding at Single Particle Level. ChemistrySelect 2023, 8 (33) https://doi.org/10.1002/slct.202302608
  53. Zhicheng Liu, Zhuolei Han, Xin Jin, Jusung An, Jaewon Kim, Wenting Chen, Jong Seung Kim, Ji Zheng, Jun Deng. Regulating the microenvironment with nanomaterials: Potential strategies to ameliorate COVID-19. Acta Pharmaceutica Sinica B 2023, 13 (9) , 3638-3658. https://doi.org/10.1016/j.apsb.2023.02.010
  54. Asaikkutti Annamalai, Vimala Karuppaiya, Dhineshkumar Ezhumalai, Praseeja Cheruparambath, Kaviarasu Balakrishnan, Arul Venkatesan. Nano-based techniques: A revolutionary approach to prevent covid-19 and enhancing human awareness. Journal of Drug Delivery Science and Technology 2023, 86 , 104567. https://doi.org/10.1016/j.jddst.2023.104567
  55. Sayan Mukherjee, Souvik Manna, Nivedita Som, Santanu Dhara. Organic–Inorganic Hybrid Nanocomposites for Nanotheranostics: Special Focus on Preventing Emerging Variants of SARS-COV-2. Biomedical Materials & Devices 2023, 1 (2) , 633-647. https://doi.org/10.1007/s44174-023-00077-w
  56. Sushma. NC, J Adlin Jino Nesalin, E. Gopinath, Vineeth Chandy. An Outlook towards Nanosponges: A Propitious Nanocarrier for Novel Drug Delivery. Asian Journal of Research in Pharmaceutical Sciences 2023, , 248-254. https://doi.org/10.52711/2231-5659.2023.00043
  57. Bedanta Bhattacharjee, Abu Md Ashif Ikbal, Atika Farooqui, Ram Kumar Sahu, Sakina Ruhi, Ayesha Syed, Andang Miatmoko, Danish Khan, Jiyauddin Khan. Superior possibilities and upcoming horizons for nanoscience in COVID-19: noteworthy approach for effective diagnostics and management of SARS-CoV-2 outbreak. Chemical Papers 2023, 77 (8) , 4107-4130. https://doi.org/10.1007/s11696-023-02795-3
  58. Feiyun Cui, Yingli Song, Haijie Ji, Mengnan Li, Xiwei Zhuang, Chijia Zeng, Bin Qu, Hongju Mao, Jufan Zhang, H. Susan Zhou, Qin Zhou. GlycoEVLR: Glycosylated extracellular vesicle-like receptors for targeting and sensing viral antigen. Chemical Engineering Journal 2023, 469 , 143844. https://doi.org/10.1016/j.cej.2023.143844
  59. Eunhye Park, So Young Choi, Jieun Kim, Niko Hildebrandt, Jin Seok Lee, Jwa‐Min Nam. Nanotechnologies for the Diagnosis and Treatment of SARS‐CoV‐2 and Its Variants. Small Methods 2023, 7 (7) https://doi.org/10.1002/smtd.202300034
  60. Rabeya Tajnur, Refaya Rezwan, Md. Abdul Aziz, Mohammad Safiqul Islam. An update on vaccine status and the role of nanomedicine against SARS‐CoV‐2: A narrative review. Health Science Reports 2023, 6 (7) https://doi.org/10.1002/hsr2.1377
  61. Qian-Fang Meng, Wanbo Tai, Mingyao Tian, Xinyu Zhuang, Yuanwei Pan, Jialin Lai, Yangtao Xu, Zhiqiang Xu, Min Li, Guangyu Zhao, Guang-Tao Yu, Guocan Yu, Rongchang Chen, Ningyi Jin, Xiao Li, Gong Cheng, Xiaoyuan Chen, Lang Rao. Inhalation delivery of dexamethasone with iSEND nanoparticles attenuates the COVID-19 cytokine storm in mice and nonhuman primates. Science Advances 2023, 9 (24) https://doi.org/10.1126/sciadv.adg3277
  62. Somayeh Handali, Ismaeil Haririan, Mohammad Vaziri, Farid Abedin Dorkoosh. Nanomedicine “New Food for an Old Mouth”: Novel Approaches for the Treatment of COVID-19. Drug Delivery Letters 2023, 13 (2) , 83-91. https://doi.org/10.2174/2210303112666220829125054
  63. Darío Perallón Mantas, Javier Sánchez Montejo, Antonio Muro Álvarez. Avances en el desarrollo de nuevas vacunas contra Fasciola hepatica. FarmaJournal 2023, 8 (1) , 49-57. https://doi.org/10.14201/fj2023814957
  64. PANKAJ SHARMA, ABHISHEK SHARMA, AVNEET GUPTA. NANOSPONGES: AS A DYNAMIC DRUG DELIVERY APPROACH FOR TARGETED DELIVERY. International Journal of Applied Pharmaceutics 2023, , 1-11. https://doi.org/10.22159/ijap.2023v15i3.46976
  65. Tatiana N. Pashirova, Zukhra M. Shaihutdinova, Vladimir F. Mironov, Patrick Masson. Biomedical Nanosystems for in vivo Detoxification: From Passive Delivery Systems to Functional Nanodevices and Nanorobots. Acta Naturae 2023, 15 (1) , 4-12. https://doi.org/10.32607/actanaturae.15681
  66. Hao Tang, Hongbo Qin, Shiting He, Qizhen Li, Huan Xu, Mengsi Sun, Jiaan Li, Shanshan Lu, Shengdong Luo, Panyong Mao, Pengjun Han, Lihua Song, Yigang Tong, Huahao Fan, Xingyu Jiang. Anti‐Coronaviral Nanocluster Restrain Infections of SARS‐CoV‐2 and Associated Mutants through Virucidal Inhibition and 3CL Protease Inactivation. Advanced Science 2023, 10 (13) https://doi.org/10.1002/advs.202207098
  67. Endong Zhang, Philana Phan, Zongmin Zhao. Cellular nanovesicles for therapeutic immunomodulation: A perspective on engineering strategies and new advances. Acta Pharmaceutica Sinica B 2023, 13 (5) , 1789-1827. https://doi.org/10.1016/j.apsb.2022.08.020
  68. Bin Tu, Yanrong Gao, Xinran An, Huiyuan Wang, Yongzhuo Huang. Localized delivery of nanomedicine and antibodies for combating COVID-19. Acta Pharmaceutica Sinica B 2023, 13 (5) , 1828-1846. https://doi.org/10.1016/j.apsb.2022.09.011
  69. Angelika Kwiatkowska, Ludomira Granicka. Anti-Viral Surfaces in the Fight against the Spread of Coronaviruses. Membranes 2023, 13 (5) , 464. https://doi.org/10.3390/membranes13050464
  70. Zhiwen Zhao, Dangge Wang, Yaping Li. Versatile biomimetic nanomedicine for treating cancer and inflammation disease. Medical Review 2023, 3 (2) , 123-151. https://doi.org/10.1515/mr-2022-0046
  71. Chenchen Zhao, Yuanwei Pan, Guocan Yu, Xing‐Zhong Zhao, Xiaoyuan Chen, Lang Rao. Vesicular Antibodies: Shedding Light on Antibody Therapeutics with Cell Membrane Nanotechnology. Advanced Materials 2023, 35 (12) https://doi.org/10.1002/adma.202207875
  72. Nasrullah Jan, Asadullah Madni, Safiullah Khan, Hassan Shah, Faizan Akram, Arshad Khan, Derya Ertas, Mohammad F. Bostanudin, Christopher H. Contag, Nureddin Ashammakhi, Yavuz Nuri Ertas. Biomimetic cell membrane‐coated poly(lactic‐ co ‐glycolic acid) nanoparticles for biomedical applications. Bioengineering & Translational Medicine 2023, 8 (2) https://doi.org/10.1002/btm2.10441
  73. Marjan Motiei, Lucian A. Lucia, Tomas Sáha, Petr Sáha. Current state-of-the-art review of nanotechnology-based therapeutics for viral pandemics: Special attention to COVID-19. Nanotechnology Reviews 2023, 12 (1) https://doi.org/10.1515/ntrev-2022-0515
  74. Yixin Wang, Zhaoting Li, Fanyi Mo, Ting-Jing Chen-Mayfield, Aryan Saini, Afton Martin LaMere, Quanyin Hu. Chemically engineering cells for precision medicine. Chemical Society Reviews 2023, 52 (3) , 1068-1102. https://doi.org/10.1039/D2CS00142J
  75. Haining Song, Haifeng Zhou, Qianqian Zhuang, Zexin Li, Fenglei Sun, Zhenlei Yuan, Youxin Lou, Guangjun Zhou, Yujun Zhao. IFE based nanosensor composed of UCNPs and Fe(II)-phenanthroline for detection of hypochlorous acid and periodic acid. Journal of Rare Earths 2023, 41 (2) , 200-207. https://doi.org/10.1016/j.jre.2022.04.005
  76. Changyin Fang, Yongping Ma. Peripheral Blood Genes Crosstalk between COVID-19 and Sepsis. International Journal of Molecular Sciences 2023, 24 (3) , 2591. https://doi.org/10.3390/ijms24032591
  77. Pranav Kumar Prabhakar, Navneet Khurana, Manish Vyas, Vikas Sharma, Gaber El-Saber Batiha, Harpreet Kaur, Jashanpreet Singh, Deepak Kumar, Neha Sharma, Ajeet Kaushik, Raj Kumar. Aspects of Nanotechnology for COVID-19 Vaccine Development and Its Delivery Applications. Pharmaceutics 2023, 15 (2) , 451. https://doi.org/10.3390/pharmaceutics15020451
  78. Alaa Mansour, Maya Romani, Anirudh Balakrishna Acharya, Betul Rahman, Elise Verron, Zahi Badran. Drug Delivery Systems in Regenerative Medicine: An Updated Review. Pharmaceutics 2023, 15 (2) , 695. https://doi.org/10.3390/pharmaceutics15020695
  79. Caleb F. Anderson, Qiong Wang, David Stern, Elissa K. Leonard, Boran Sun, Kyle J. Fergie, Chang-yong Choi, Jamie B. Spangler, Jason Villano, Andrew Pekosz, Cory F. Brayton, Hongpeng Jia, Honggang Cui. Supramolecular filaments for concurrent ACE2 docking and enzymatic activity silencing enable coronavirus capture and infection prevention. Matter 2023, 6 (2) , 583-604. https://doi.org/10.1016/j.matt.2022.11.027
  80. Arpita Adhikari, Dibyakanti Mandal, Dipak Rana, Jyotishka Nath, Aparajita Bose, Sonika, Jonathan Tersur Orasugh, Sriparna De, Dipankar Chattopadhyay. COVID-19 mitigation: nanotechnological intervention, perspective, and future scope. Materials Advances 2023, 4 (1) , 52-78. https://doi.org/10.1039/D2MA00797E
  81. Yuxuan Gong, Huaying Liu, Shen Ke, Li Zhuo, Haibin Wang. Latest advances in biomimetic nanomaterials for diagnosis and treatment of cardiovascular disease. Frontiers in Cardiovascular Medicine 2023, 9 https://doi.org/10.3389/fcvm.2022.1037741
  82. Ramalingam Karthik Raja, Phuong Nguyen-Tri, Govindasamy Balasubramani, Arun Alagarsamy, Selcuk Hazir, Safa Ladhari, Alireza Saidi, Arivalagan Pugazhendhi, Arulandhu Anthoni Samy. SARS-CoV-2 and its new variants: a comprehensive review on nanotechnological application insights into potential approaches. Applied Nanoscience 2023, 13 (1) , 65-93. https://doi.org/10.1007/s13204-021-01900-w
  83. Yaou Duan, Dan Wang, Shuyan Wang, Zhidong Zhou, Anvita Komarla, Julia Zhou, Qiangzhe Zhang, Xiangzhao Ai, Weiwei Gao, Liangfang Zhang. Cell membrane-coated nanoparticles and their biomedical applications. 2023, 519-542. https://doi.org/10.1016/B978-0-12-822425-0.00020-8
  84. Mohd Yusuf, Saurabh Sharma, Shafat Ahmad Khan, Lalit Prasad, Nafisa. Current applications of biomolecules as anticoronavirus drugs. 2023, 355-369. https://doi.org/10.1016/B978-0-323-91684-4.00004-9
  85. Yasmine Radwan, Ali H. Karaly, Ibrahim M. El-Sherbiny. Nanovesicles for delivery of antiviral agents. 2023, 493-518. https://doi.org/10.1016/B978-0-323-91814-5.00001-5
  86. Sandhya Khunger. Antiviral biomaterials. 2023, 519-536. https://doi.org/10.1016/B978-0-323-91814-5.00002-7
  87. Lakshmi Kanth Kotarkonda, Tej Prakash Sinha, Sanjeev Bhoi, Subhashini Bharathala. Role of nanocomposites for the prevention and treatment of viral infections in the health care system. 2023, 219-244. https://doi.org/10.1016/B978-0-323-99148-3.00012-1
  88. Kalam Mary Swarnalatha, Divyam Kumar Singh, Palugu Pavithra Reddy, Talari Ravi Teja, V T Iswariya, T Rama Rao. A REVIEW ON NANOSPONGES AND POLYMERS USED IN THEIR PRODUCTION. INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH 2023, , 61-64. https://doi.org/10.36106/ijsr/3502059
  89. Pragya Malik, Durgesh Nandini, Bijay P. Tripathi. Characterization Techniques for Nanosponges. 2023, 61-86. https://doi.org/10.1007/978-3-031-41077-2_4
  90. Prajkta Chivte, Vinal Pardhi, Akhilraj Pillai. Biological Methods for Drug Delivery. 2023, 1-20. https://doi.org/10.1007/978-981-99-6564-9_1
  91. Jingmei Li, Jin Zhang, Yan Gao, Sibei Lei, Jieping Wu, Xiaohua Chen, Kaiyu Wang, Xingmei Duan, Ke Men. Targeted siRNA Delivery by Bioinspired Cancer Cell Membrane-Coated Nanoparticles with Enhanced Anti-Cancer Immunity. International Journal of Nanomedicine 2023, Volume 18 , 5961-5982. https://doi.org/10.2147/IJN.S429036
  92. Shuyan Wang, Dan Wang, Mingxuan Kai, Wei-Ting Shen, Lei Sun, Weiwei Gao, Liangfang Zhang. Design Strategies for Cellular Nanosponges as Medical Countermeasures. BME Frontiers 2023, 4 https://doi.org/10.34133/bmef.0018
  93. Jingjing Yan, Weidong Fei, Qianqian Song, Yao Zhu, Na Bu, Li Wang, Mengdan Zhao, Xiaoling Zheng. Cell membrane-camouflaged PLGA biomimetic system for diverse biomedical application. Drug Delivery 2022, 29 (1) , 2296-2319. https://doi.org/10.1080/10717544.2022.2100010
  94. Govind Gupta, Bejan Hamawandi, Daniel J. Sheward, Ben Murrell, Leo Hanke, Gerald McInerney, Magda Blosi, Anna L. Costa, Muhammet S. Toprak, Bengt Fadeel. Silver nanoparticles with excellent biocompatibility block pseudotyped SARS-CoV-2 in the presence of lung surfactant. Frontiers in Bioengineering and Biotechnology 2022, 10 https://doi.org/10.3389/fbioe.2022.1083232
  95. Reema Iqbal, Sadia Khan, Haroon Muhammad Ali, Maham Khan, Shahid Wahab, Tariq Khan. Application of nanomaterials against SARS-CoV-2: An emphasis on their usefulness against emerging variants of concern. Frontiers in Nanotechnology 2022, 4 https://doi.org/10.3389/fnano.2022.1060756
  96. Lizhi Liu, Wei Yu, Jani Seitsonen, Wujun Xu, Vesa‐Pekka Lehto. Correct Identification of the Core‐Shell Structure of Cell Membrane‐Coated Polymeric Nanoparticles. Chemistry – A European Journal 2022, 28 (68) https://doi.org/10.1002/chem.202200947
  97. Huaxing Dai, Qin Fan, Chao Wang. Recent applications of immunomodulatory biomaterials for disease immunotherapy. Exploration 2022, 2 (6) https://doi.org/10.1002/EXP.20210157
  98. Helen Forgham, Aleksandr Kakinen, Ruirui Qiao, Thomas P. Davis. Keeping up with the COVID's—Could siRNA‐based antivirals be a part of the answer?. Exploration 2022, 2 (6) https://doi.org/10.1002/EXP.20220012
  99. Wenzhe Yi, Ping Xiao, Xiaochen Liu, Zitong Zhao, Xiangshi Sun, Jue Wang, Lei Zhou, Guanru Wang, Haiqiang Cao, Dangge Wang, Yaping Li. Recent advances in developing active targeting and multi-functional drug delivery systems via bioorthogonal chemistry. Signal Transduction and Targeted Therapy 2022, 7 (1) https://doi.org/10.1038/s41392-022-01250-1
  100. Lizhi Liu, Dingyi Pan, Sheng Chen, Maria-Viola Martikainen, Anna Kårlund, Jing Ke, Herkko Pulkkinen, Hanna Ruhanen, Marjut Roponen, Reijo Käkelä, Wujun Xu, Jie Wang, Vesa-Pekka Lehto. Systematic design of cell membrane coating to improve tumor targeting of nanoparticles. Nature Communications 2022, 13 (1) https://doi.org/10.1038/s41467-022-33889-3
Load more citations
Download PDF

  • Abstract

    High Resolution Image
    Download MS PowerPoint Slide

    Figure 1

    Figure 1. Fabrication and characterization of cellular nanosponges. (A) Schematic mechanism of cellular nanosponges inhibiting SARS-CoV-2 infectivity. The nanosponges were constructed by wrapping polymeric nanoparticle (NP) cores with natural cell membranes from target cells such as lung epithelial cells and macrophages (MΦs). The resulting nanosponges (denoted “Epithelial-NS” and “MΦ-NS”, respectively) inherit the surface antigen profiles of the source cells and serve as decoys to bind with SARS-CoV-2. Such binding interaction blocks viral entry and inhibits viral infectivity. (B) Dynamic light scattering measurements of hydrodynamic size (diameter, nm) and surface zeta-potential (ζ, mV) of polymeric NP cores before and after coating with cell membranes (n = 3; mean + standard deviation). (C) Selective protein bands of cell lysate, cell membrane vesicles, and cellular nanosponges resolved with Western blotting analysis. (D) Comparison of the fluorescence intensity measured from cellular nanosponges (100 μL, 0.5 mg/mL membrane protein concentration) or source cells (100 μL, approximately 2.5 × 106 cells) containing equal amounts of membrane content and stained with fluorescently labeled antibodies (n = 3; mean + standard deviation; n.s.: not significant; statistical analysis was performed with paired two-tailed t-test). (E) Stability of cellular nanosponges in 1× phosphate-buffered saline determined by monitoring particle size (diameter, nm) over a span of 7 days (n = 3; mean ± standard deviation).

    High Resolution Image
    Download MS PowerPoint Slide

    Figure 2

    Figure 2. In vivo safety of cellular nanosponges. (A) Hematoxylin and eosin (H&E) staining of representative lung sections taken 3 days after intratracheal administration of the cellular nanosponges (scale bar: 250 μm). (B) Comprehensive serum chemistry panel performed 3 days after intratracheal administration of the cellular nanosponges (n = 3; mean + standard deviation). ALB, albumin; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AMY, amylase; BUN, urea nitrogen; CA, calcium; CRE, creatinine; GLOB, globulin (calculated); GLU, glucose; K+, potassium; NA+, sodium; PHOS, phosphorus; TBIL, total bilirubin; TP, total protein. (C) Blood cell counts 3 days after intratracheal administration of cellular nanosponges (n = 3; mean + standard deviation).

    High Resolution Image
    Download MS PowerPoint Slide

    Figure 3

    Figure 3. Cellular nanosponges neutralize SARS-CoV-2 infectivity. The neutralization against SARS-CoV-2 infection by (A) Epithelial-NS, (B) MΦ-NS, and (C) nanosponges made from red blood cell membranes (RBC-NS, used as a control) was tested using live SARS-CoV-2 viruses on Vero E6 cells. The IC50 values for Epithelial-NS and MΦ-NS were found to be 827.1 and 882.7 μg/mL (membrane protein concentration), respectively. In all data sets, n = 3. Data are presented as mean + standard deviation. Horizontal dashed lines mark the zero levels. IC50 values were derived from the variable slope model using Graphpad Prism 8.

    High Resolution Image
    Download MS PowerPoint Slide

  • References

    ARTICLE SECTIONS
    Jump To

    This article references 20 other publications.

    1. 1
      Munster, V. J.; Koopmans, M.; van Doremalen, N.; van Riel, D.; de Wit, E. A novel coronavirus emerging in china - key questions for impact assessment. N. Engl. J. Med. 2020, 382, 692– 694,  DOI: 10.1056/NEJMp2000929
      1
      A novel coronavirus emerging in China - key questions for impact assessment
      Munster, Vincent J.; Koopmans, Marion; van Doremalen, Neeltje; van Riel, Debby; de Wit, Emmie
      New England Journal of Medicine (2020), 382 (8), 692-694CODEN: NEJMAG; ISSN:1533-4406. (Massachusetts Medical Society)
      A review. After initial reports of a SARS-like virus emerging in Wuhan, it appears that SARS-CoV-2 (2019-nCoV) may be less pathogenic than MERS-CoV and SARS-CoV. However, the virus's emergence raises an important question: What is the role of overall pathogenicity in our ability to contain emerging viruses, prevent large-scale spread, and prevent them from causing a pandemic or becoming endemic in the human population. Important questions regarding any emerging virus concern the shape of the disease pyramid, the proportion of infected people who develop disease, and the proportion of those who seek health care; these three points inform the classic surveillance pyramid. Emerging coronaviruses raise an addnl. question of how widespread the virus is in its reservoir. Epidemiol. information on the pathogenicity and transmissibility of this virus obtained by means of mol. detection and serosurveillance is needed to fill in the details in the surveillance pyramid and guide the response to this outbreak. Moreover, the propensity of novel coronaviruses to spread in health care centers indicates a need for peripheral health care facilities to be on standby to identify potential cases as well. In addn., increased preparedness is needed at animal markets and other animal facilities, while the possible source of this emerging virus is being investigated.
      >> More from SciFinder ®
      https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjslGltrk%253D&md5=6af431f001d8a97fa0fea77441998489
    2. 2
      Wu, D.; Wu, T. T.; Liu, Q.; Yang, Z. C. The SARS-CoV-2 outbreak: What we know. Int. J. Infect. Dis. 2020, 94, 44– 48,  DOI: 10.1016/j.ijid.2020.03.004
      2
      The SARS-CoV-2 outbreak: What we know
      Wu, Di; Wu, Tiantian; Liu, Qun; Yang, Zhicong
      International Journal of Infectious Diseases (2020), 94 (), 44-48CODEN: IJIDF3; ISSN:1201-9712. (Elsevier Ltd.)
      A review. There is a current worldwide outbreak of the novel coronavirus Covid-19 (coronavirus disease 2019; the pathogen called SARS-CoV-2; previously 2019-nCoV), which originated from Wuhan in China and has now spread to 6 continents including 66 countries, as of 24:00 on March 2, 2020. Governments are under increased pressure to stop the outbreak from spiraling into a global health emergency. At this stage, preparedness, transparency, and sharing of information are crucial to risk assessments and beginning outbreak control activities. This information should include reports from outbreak site and from labs. supporting the investigation. This paper aggregates and consolidates the epidemiol., clin. manifestations, diagnosis, treatments and preventions of this new type of coronavirus.
      >> More from SciFinder ®
      https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXntlensbY%253D&md5=b0d3662114f26b797adf9beaa28952d7
    3. 3
      Wang, Y.; Zhang, D.; Du, G.; Du, R.; Zhao, J.; Jin, Y.; Fu, S.; Gao, L.; Cheng, Z.; Lu, Q.; Hu, Y.; Luo, G.; Wang, K.; Lu, Y.; Li, H.; Wang, S.; Ruan, S.; Yang, C.; Mei, C.; Wang, Y.; Ding, D.; Wu, F.; Tang, X.; Ye, X.; Ye, Y.; Liu, B.; Yang, J.; Yin, W.; Wang, A.; Fan, G.; Zhou, F.; Liu, Z.; Gu, X.; Xu, J.; Shang, L.; Zhang, Y.; Cao, L.; Guo, T.; Wan, Y.; Qin, H.; Jiang, Y.; Jaki, T.; Hayden, F. G.; Horby, P. W.; Cao, B.; Wang, C. Remdesivir in adults with severe COVID-19: A randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2020, 395, 1569– 1578,  DOI: 10.1016/S0140-6736(20)31022-9
      3
      Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial
      Wang, Yeming; Zhang, Dingyu; Du, Guanhua; Du, Ronghui; Zhao, Jianping; Jin, Yang; Fu, Shouzhi; Gao, Ling; Cheng, Zhenshun; Lu, Qiaofa; Hu, Yi; Luo, Guangwei; Wang, Ke; Lu, Yang; Li, Huadong; Wang, Shuzhen; Ruan, Shunan; Yang, Chengqing; Mei, Chunlin; Wang, Yi; Ding, Dan; Wu, Feng; Tang, Xin; Ye, Xianzhi; Ye, Yingchun; Liu, Bing; Yang, Jie; Yin, Wen; Wang, Aili; Fan, Guohui; Zhou, Fei; Liu, Zhibo; Gu, Xiaoying; Xu, Jiuyang; Shang, Lianhan; Zhang, Yi; Cao, Lianjun; Guo, Tingting; Wan, Yan; Qin, Hong; Jiang, Yushen; Jaki, Thomas; Hayden, Frederick G.; Horby, Peter W.; Cao, Bin; Wang, Chen
      Lancet (2020), 395 (10236), 1569-1578CODEN: LANCAO; ISSN:0140-6736. (Elsevier Ltd.)
      No specific antiviral drug has been proven effective for treatment of patients with severe coronavirus disease 2019 (COVID-19). Remdesivir (GS-5734), a nucleoside analog prodrug, has inhibitory effects on pathogenic animal and human coronaviruses, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in vitro, and inhibits Middle East respiratory syndrome coronavirus, SARS-CoV-1, and SARS-CoV-2 replication in animal models. We did a randomized, double-blind, placebo-controlled, multicenter trial at ten hospitals in Hubei, China. Eligible patients were adults (aged ≥18 years) admitted to hospital with lab.-confirmed SARS-CoV-2 infection, with an interval from symptom onset to enrollment of 12 days or less, oxygen satn. of 94% or less on room air or a ratio of arterial oxygen partial pressure to fractional inspired oxygen of 300 mm Hg or less, and radiol. confirmed pneumonia. Patients were randomly assigned in a 2:1 ratio to i.v. remdesivir (200 mg on day 1 followed by 100 mg on days 2-10 in single daily infusions) or the same vol. of placebo infusions for 10 days. Patients were permitted concomitant use of lopinavir-ritonavir, interferons, and corticosteroids. The primary endpoint was time to clin. improvement up to day 28, defined as the time (in days) from randomization to the point of a decline of two levels on a six-point ordinal scale of clin. status (from 1=discharged to 6=death) or discharged alive from hospital, whichever came first. Primary anal. was done in the intention-to-treat (ITT) population and safety anal. was done in all patients who started their assigned treatment. This trial is registered with ClinicalTrials.gov, NCT04257656. Between Feb 6, 2020, and March 12, 2020, 237 patients were enrolled and randomly assigned to a treatment group (158 to remdesivir and 79 to placebo); one patient in the placebo group who withdrew after randomization was not included in the ITT population. Remdesivir use was not assocd. with a difference in time to clin. improvement (hazard ratio 1·23 [95% CI 0·87-1·75]). Although not statistically significant, patients receiving remdesivir had a numerically faster time to clin. improvement than those receiving placebo among patients with symptom duration of 10 days or less (hazard ratio 1·52 [0·95-2·43]). Adverse events were reported in 102 (66%) of 155 remdesivir recipients vs. 50 (64%) of 78 placebo recipients. Remdesivir was stopped early because of adverse events in 18 (12%) patients vs. four (5%) patients who stopped placebo early. In this study of adult patients admitted to hospital for severe COVID-19, remdesivir was not assocd. with statistically significant clin. benefits. However, the numerical redn. in time to clin. improvement in those treated earlier requires confirmation in larger studies. Chinese Academy of Medical Sciences Emergency Project of COVID-19, National Key Research and Development Program of China, the Beijing Science and Technol. Project.
      >> More from SciFinder ®
      https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXosVWlurc%253D&md5=160af7f665ed7fe089e9c07b3bec1acd
    4. 4
      Bekerman, E.; Einav, S. Combating emerging viral threats. Science 2015, 348, 282– 283,  DOI: 10.1126/science.aaa3778
      4
      Combating emerging viral threats
      Bekerman, Elena; Einav, Shirit
      Science (Washington, DC, United States) (2015), 348 (6232), 282-283CODEN: SCIEAS; ISSN:0036-8075. (American Association for the Advancement of Science)
      There is no expanded citation for this reference.
      >> More from SciFinder ®
      https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXosVKjt7Y%253D&md5=1cf54cc0a7db0925573f96ed72c27c11
    5. 5
      Catanzaro, M.; Fagiani, F.; Racchi, M.; Corsini, E.; Govoni, S.; Lanni, C. Immune response in COVID-19: Addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2. Signal Transduct. Target. Ther. 2020, 5, 84,  DOI: 10.1038/s41392-020-0191-1
      5
      Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2
      Catanzaro Michele; Fagiani Francesca; Racchi Marco; Govoni Stefano; Lanni Cristina; Fagiani Francesca; Corsini Emanuela
      Signal transduction and targeted therapy (2020), 5 (1), 84 ISSN:.
      To date, no vaccines or effective drugs have been approved to prevent or treat COVID-19 and the current standard care relies on supportive treatments. Therefore, based on the fast and global spread of the virus, urgent investigations are warranted in order to develop preventive and therapeutic drugs. In this regard, treatments addressing the immunopathology of SARS-CoV-2 infection have become a major focus. Notably, while a rapid and well-coordinated immune response represents the first line of defense against viral infection, excessive inflammatory innate response and impaired adaptive host immune defense may lead to tissue damage both at the site of virus entry and at systemic level. Several studies highlight relevant changes occurring both in innate and adaptive immune system in COVID-19 patients. In particular, the massive cytokine and chemokine release, the so-called "cytokine storm", clearly reflects a widespread uncontrolled dysregulation of the host immune defense. Although the prospective of counteracting cytokine storm is compelling, a major limitation relies on the limited understanding of the immune signaling pathways triggered by SARS-CoV-2 infection. The identification of signaling pathways altered during viral infections may help to unravel the most relevant molecular cascades implicated in biological processes mediating viral infections and to unveil key molecular players that may be targeted. Thus, given the key role of the immune system in COVID-19, a deeper understanding of the mechanism behind the immune dysregulation might give us clues for the clinical management of the severe cases and for preventing the transition from mild to severe stages.
      >> More from SciFinder ®
      https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB38rivVOmuw%253D%253D&md5=3fb8e4f85321d6225c5c4922661eab10
    6. 6
      Zumla, A.; Chan, J. F. W.; Azhar, E. I.; Hui, D. S. C.; Yuen, K. Y. Coronaviruses - drug discovery and therapeutic options. Nat. Rev. Drug Discovery 2016, 15, 327– 347,  DOI: 10.1038/nrd.2015.37
      6
      Coronaviruses - drug discovery and therapeutic options
      Zumla, Alimuddin; Chan, Jasper F. W.; Azhar, Esam I.; Hui, David S. C.; Yuen, Kwok-Yung
      Nature Reviews Drug Discovery (2016), 15 (5), 327-347CODEN: NRDDAG; ISSN:1474-1776. (Nature Publishing Group)
      A review. In humans, infections with the human coronavirus (HCoV) strains HCoV-229E, HCoV-OC43, HCoV-NL63 and HCoV-HKU1 usually result in mild, self-limiting upper respiratory tract infections, such as the common cold. By contrast, the CoVs responsible for severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), which were discovered in Hong Kong, China, in 2003, and in Saudi Arabia in 2012, resp., have received global attention over the past 12 years owing to their ability to cause community and health-care-assocd. outbreaks of severe infections in human populations. These two viruses pose major challenges to clin. management because there are no specific antiviral drugs available. In this Review, we summarize the epidemiol., virol., clin. features and current treatment strategies of SARS and MERS, and discuss the discovery and development of new virus-based and host-based therapeutic options for CoV infections.
      >> More from SciFinder ®
      https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XisVyru70%253D&md5=437159fc2f3885395268bd6d97e34a0b
    7. 7
      Tay, M. Z.; Poh, C. M.; Renia, L.; MacAry, P. A.; Ng, L. F. P. The trinity of COVID-19: Immunity, inflammation and intervention. Nat. Rev. Immunol. 2020, 20, 363– 374,  DOI: 10.1038/s41577-020-0311-8
      7
      The trinity of COVID-19: immunity, inflammation and intervention
      Tay, Matthew Zirui; Poh, Chek Meng; Renia, Laurent; MacAry, Paul A.; Ng, Lisa F. P.
      Nature Reviews Immunology (2020), 20 (6), 363-374CODEN: NRIABX; ISSN:1474-1733. (Nature Research)
      A review. A review. Abstr.: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the ongoing coronavirus disease 2019 (COVID-19) pandemic. Alongside investigations into the virol. of SARS-CoV-2, understanding the fundamental physiol. and immunol. processes underlying the clin. manifestations of COVID-19 is vital for the identification and rational design of effective therapies. Here, we provide an overview of the pathophysiol. of SARS-CoV-2 infection. We describe the interaction of SARS-CoV-2 with the immune system and the subsequent contribution of dysfunctional immune responses to disease progression. From nascent reports describing SARS-CoV-2, we make inferences on the basis of the parallel pathophysiol. and immunol. features of the other human coronaviruses targeting the lower respiratory tract - severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV). Finally, we highlight the implications of these approaches for potential therapeutic interventions that target viral infection and/or immunoregulation.
      >> More from SciFinder ®
      https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXot1aksbw%253D&md5=3513ef4a1bfc1dd043269044484bdb44
    8. 8
      Pei, G.; Zhang, Z.; Peng, J.; Liu, L.; Zhang, C.; Yu, C.; Ma, Z.; Huang, Y.; Liu, W.; Yao, Y.; Zeng, R.; Xu, G. Renal involvement and early prognosis in patients with COVID-19 pneumonia. J. Am. Soc. Nephrol. 2020, 31, 1157– 1165,  DOI: 10.1681/ASN.2020030276
      8
      Renal involvement and early prognosis in patients with COVID-19 pneumonia
      Pei, Guangchang; Zhang, Zhiguo; Peng, Jing; Liu, Liu; Zhang, Chunxiu; Yu, Chong; Ma, Zufu; Huang, Yi; Liu, Wei; Yao, Ying; Zeng, Rui; Xu, Gang
      Journal of the American Society of Nephrology (2020), 31 (6), 1157-1165CODEN: JASNEU; ISSN:1046-6673. (American Society of Nephrology)
      Background: Some patients with COVID-19 pneumonia also present with kidney injury, and autopsy findings of patients who died from the illness sometimes show renal damage. However, little is known about the clin. characteristics of kidney-related complications, including hematuria, proteinuria, and AKI. Methods: In this retrospective, single-center study in China, we analyzed data from electronic medical records of 333 hospitalized patients with COVID-19 pneumonia, including information about clin., lab., radiol., and other characteristics, as well as information about renal outcomes. Results: We found that 251 of the 333 patients (75.4%) had abnormal urine dipstick tests or AKI. Of 198 patients with renal involvement for the median duration of 12 days, 118 (59.6%) experienced remission of pneumonia during this period, and 111 of 162 (68.5%) patients experienced remission of proteinuria. Among 35 patients who developed AKI (with AKI identified by criteria expanded somewhat beyond the 2012 Kidney Disease: Improving Global Outcomes definition), 16 (45.7%) experienced complete recovery of kidney function. We suspect that most AKI cases were intrinsic AKI. Patients with renal involvement had higher overall mortality compared with those without renal involvement (28 of 251 [11.2%] vs. one of 82 [1.2%], resp.). Stepwise multivariate binary logistic regression analyses showed that severity of pneumonia was the risk factor most commonly assocd. with lower odds of proteinuric or hematuric remission and recovery from AKI. Conclusions: Renal abnormalities occurred in the majority of patients with COVID-19 pneumonia. Although proteinuria, hematuria, and AKI often resolved in such patients within 3 wk after the onset of symptoms, renal complications in COVID-19 were assocd. with higher mortality.
      >> More from SciFinder ®
      https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitFCqsrjI&md5=13a3b6835152e54faeb73a31819c9917
    9. 9
      Zangrillo, A.; Beretta, L.; Scandroglio, A. M.; Monti, G.; Fominskiy, E.; Colombo, S.; Morselli, F.; Belletti, A.; Silvani, P.; Crivellari, M.; Monaco, F.; Azzolini, M. L.; Reineke, R.; Nardelli, P.; Sartorelli, M.; Votta, C. D.; Ruggeri, A.; Ciceri, F.; Cobelli, F. D.; Tresoldi, M.-n.; Dagna, L.; Rovere-Querini, P.; Neto, A. S.; Bellomo, R.; Landon, G. Characteristics, treatment, outcomes and cause of death of invasively ventilated patients with COVID-19 ARDS in Milan, Italy. Crit. Care Resusc. 2020; published online ahead of print.
      There is no corresponding record for this reference.
    10. 10
      Ye, Q.; Wang, B.; Mao, J. The pathogenesis and treatment of the ‘cytokine storm’ in COVID-19. J. Infect. 2020, 80, 607– 613,  DOI: 10.1016/j.jinf.2020.03.037
      10
      The pathogenesis and treatment of the 'Cytokine Storm' in COVID-19
      Ye, Qing; Wang, Bili; Mao, Jianhua
      Journal of Infection (2020), 80 (6), 607-613CODEN: JINFD2; ISSN:0163-4453. (Elsevier B.V.)
      A review. Cytokine storm is a general term applied to maladaptive cytokine release in response to infection and other stimuli. The pathogenesis is complex but includes loss of regulatory control of proinflammatory cytokine prodn., both at local and systemic levels. The disease progresses rapidly, and the mortality is high. Some evidence shows that, during the coronavirus disease 2019 (COVID-19) epidemic, severe deterioration in some patients has been closely assocd. with dysregulated and excessive cytokine release. This article reviews what we know of the mechanism and treatment strategies of the COVID-19 virus-induced inflammatory storm in an attempt to provide some background to inform future guidance for clin. treatment.
      >> More from SciFinder ®
      https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtVantL%252FP&md5=21ad8db56c54cab280db18e344231dab
    11. 11
      Connors, J. M.; Levy, J. H. COVID-19 and its implications for thrombosis and anticoagulation. Blood 2020, 135, 2033– 2040,  DOI: 10.1182/blood.2020006000
      11
      COVID-19 and its implications for thrombosis and anticoagulation
      Connors, Jean M.; Levy, Jerrold H.
      Blood (2020), 135 (23), 2033-2040CODEN: BLOOAW; ISSN:1528-0020. (American Society of Hematology)
      Severe acute respiratory syndrome coronavirus 2, coronavirus disease 2019 (COVID-19)-induced infection can be assocd. with a coagulopathy, findings consistent with infection-induced inflammatory changes as obsd. in patients with disseminated intravascular coagulopathy (DIC). The lack of prior immunity to COVID-19 has resulted in large nos. of infected patients across the globe and uncertainty regarding management of the complications that arise in the course of this viral illness. The lungs are the target organ for COVID-19; patients develop acute lung injury that can progress to respiratory failure, although multiorgan failure can also occur. The initial coagulopathy of COVID-19 presents with prominent elevation of D-dimer and fibrin/fibrinogen-degrdn. products, whereas abnormalities in prothrombin time, partial thromboplastin time, and platelet counts are relatively uncommon in initial presentations. Coagulation test screening, including the measurement of D-dimer and fibrinogen levels, is suggested. COVID-19-assocd. coagulopathy should be managed as it would be for any critically ill patient, following the established practice of using thromboembolic prophylaxis for critically ill hospitalized patients, and std. supportive care measures for those with sepsis-induced coagulopathy or DIC. Although D-dimer, sepsis physiol., and consumptive coagulopathy are indicators of mortality, current data do not suggest the use of full-intensity anticoagulation doses unless otherwise clin. indicated. Even though there is an assocd. coagulopathy with COVID-19, bleeding manifestations, even in those with DIC, have not been reported. If bleeding does occur, std. guidelines for the management of DIC and bleeding should be followed.
      >> More from SciFinder ®
      https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtlSjs7nJ&md5=850a0e9f6688ac64f69dd016403ae9dc
    12. 12
      Yan, R. H.; Zhang, Y. Y.; Li, Y. N.; Xia, L.; Guo, Y. Y.; Zhou, Q. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science 2020, 367, 1444– 1448,  DOI: 10.1126/science.abb2762
      12
      Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2
      Yan, Renhong; Zhang, Yuanyuan; Li, Yaning; Xia, Lu; Guo, Yingying; Zhou, Qiang
      Science (Washington, DC, United States) (2020), 367 (6485), 1444-1448CODEN: SCIEAS; ISSN:1095-9203. (American Association for the Advancement of Science)
      Angiotensin-converting enzyme 2 (ACE2) is the cellular receptor for severe acute respiratory syndrome coronavirus (SARS-CoV) and the new coronavirus (SARS-CoV-2) that is causing the serious coronavirus disease 2019 (COVID-19) epidemic. Here, we present cryo-electron microscopy structures of full-length human ACE2 in the presence of the neutral amino acid transporter B0AT1 with or without the receptor binding domain (RBD) of the surface spike glycoprotein (S protein) of SARS-CoV-2, both at an overall resoln. of 2.9 angstroms, with a local resoln. of 3.5 angstroms at the ACE2-RBD interface. The ACE2-B0AT1 complex is assembled as a dimer of heterodimers, with the collectrin-like domain of ACE2 mediating homodimerization. The RBD is recognized by the extracellular peptidase domain of ACE2 mainly through polar residues. These findings provide important insights into the mol. basis for coronavirus recognition and infection.
      >> More from SciFinder ®
      https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXlslymsLo%253D&md5=ff4dfdfc646ea878cfb325019160e94a
    13. 13
      Qi, F.; Qian, S.; Zhang, S.; Zhang, Z. Single cell rna sequencing of 13 human tissues identify cell types and receptors of human coronaviruses. Biochem. Biophys. Res. Commun. 2020, 526, 135– 140,  DOI: 10.1016/j.bbrc.2020.03.044
      13
      Single cell RNA sequencing of 13 human tissues identify cell types and receptors of human coronaviruses
      Qi, Furong; Qian, Shen; Zhang, Shuye; Zhang, Zheng
      Biochemical and Biophysical Research Communications (2020), 526 (1), 135-140CODEN: BBRCA9; ISSN:0006-291X. (Elsevier B.V.)
      The new coronavirus (SARS-CoV-2) outbreak from Dec. 2019 in Wuhan, Hubei, China, has been declared a global public health emergency. Angiotensin I converting enzyme 2 (ACE2), is the host receptor by SARS-CoV-2 to infect human cells. Although ACE2 is reported to be expressed in lung, liver, stomach, ileum, kidney and colon, its expressing levels are rather low, esp. in the lung. SARS-CoV-2 may use co-receptors/auxiliary proteins as ACE2 partner to facilitate the virus entry. To identify the potential candidates, we explored the single cell gene expression atlas including 119 cell types of 13 human tissues and analyzed the single cell co-expression spectrum of 51 reported RNA virus receptors and 400 other membrane proteins. Consistent with other recent reports, we confirmed that ACE2 was mainly expressed in lung AT2, liver cholangiocyte, colon colonocytes, esophagus keratinocytes, ileum ECs, rectum ECs, stomach epithelial cells, and kidney proximal tubules. Intriguingly, we found that the candidate co-receptors, manifesting the most similar expression patterns with ACE2 across 13 human tissues, are all peptidases, including ANPEP, DPP4 and ENPEP. Among them, ANPEP and DPP4 are the known receptors for human CoVs, suggesting ENPEP as another potential receptor for human CoVs. We also conducted "CellPhoneDB" anal. to understand the cell crosstalk between CoV-targets and their surrounding cells across different tissues. We found that macrophages frequently communicate with the CoVs targets through chemokine and phagocytosis signaling, highlighting the importance of tissue macrophages in immune defense and immune pathogenesis.
      >> More from SciFinder ®
      https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXlt1Wrt78%253D&md5=7f484d8f3654456f18e7a7ca9c5dd80a
    14. 14
      Luk, B. T.; Hu, C. M. J.; Fang, R. N. H.; Dehaini, D.; Carpenter, C.; Gao, W.; Zhang, L. Interfacial interactions between natural RBC membranes and synthetic polymeric nanoparticles. Nanoscale 2014, 6, 2730– 2737,  DOI: 10.1039/C3NR06371B
      14
      Interfacial interactions between natural RBC membranes and synthetic polymeric nanoparticles
      Luk, Brian T.; Jack Hu, Che-Ming; Fang, Ronnie H.; Dehaini, Diana; Carpenter, Cody; Gao, Weiwei; Zhang, Liangfang
      Nanoscale (2014), 6 (5), 2730-2737CODEN: NANOHL; ISSN:2040-3372. (Royal Society of Chemistry)
      The unique structural features and stealth properties of a recently developed red blood cell membrane-cloaked nanoparticle (RBC-NP) platform raise curiosity over the interfacial interactions between natural cellular membranes and polymeric nanoparticle substrates. Herein, several interfacial aspects of the RBC-NPs are examd., including completeness of membrane coverage, membrane sidedness upon coating, and the effects of polymeric particles' surface charge and surface curvature on the membrane cloaking process. The study shows that RBC membranes completely cover neg. charged polymeric nanoparticles in a right-side-out manner and enhance the particles' colloidal stability. The membrane cloaking process is applicable to particle substrates with a diam. ranging from 65 to 340 nm. Addnl., the study reveals that both surface glycans on RBC membranes and the substrate properties play a significant role in driving and directing the membrane-particle assembly. These findings further the understanding of the dynamics between cellular membranes and nanoscale substrates and provide valuable information toward future development and characterization of cellular membrane-cloaked nanodevices.
      >> More from SciFinder ®
      https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXisVahtbo%253D&md5=c27d7e12b232e07e284e60572bf1f104
    15. 15
      Wei, X. L.; Zhang, G.; Ran, D. N.; Krishnan, N.; Fang, R. H.; Gao, W.; Spector, S. A.; Zhang, L. T-cell-mimicking nanoparticles can neutralize HIV infectivity. Adv. Mater. 2018, 30, 1802233,  DOI: 10.1002/adma.201802233
      There is no corresponding record for this reference.
    16. 16
      Harcourt, J.; Tamin, A.; Lu, X.; Kamili, S.; Sakthivel, S. K.; Murray, J.; Queen, K.; Tao, Y.; Paden, C. R.; Zhang, J.; Li, Y.; Uehara, A.; Wang, H.; Goldsmith, C.; Bullock, H. A.; Wang, L.; Whitaker, B.; Lynch, B.; Gautam, R.; Schindewolf, C.; Lokugamage, K. G.; Scharton, D.; Plante, J. A.; Mirchandani, D.; Widen, S. G.; Narayanan, K.; Makino, S.; Ksiazek, T. G.; Plante, K. S.; Weaver, S. C.; Lindstrom, S.; Tong, S.; Menachery, V. D.; Thornburg, N. J. Severe acute respiratory syndrome coronavirus 2 from patient with 2019 novel coronavirus disease, United States. Emerging Infect. Dis. 2020, 26, 1266– 1273,  DOI: 10.3201/eid2606.200516
      16
      Severe acute respiratory syndrome coronavirus 2 from patient with coronavirus disease, United States
      Harcourt, Jennifer; Tamin, Azaibi; Lu, Xiaoyan; Kamili, Shifaq; Sakthivel, Senthil K.; Murray, Janna; Queen, Krista; Tao, Ying; Paden, Clinton R.; Zhang, Jing; Li, Yan; Uehara, Anna; Wang, Haibin; Goldsmith, Cynthia; Bullock, Hannah A.; Wang, Lijuan; Whitaker, Brett; Lynch, Brian; Gautam, Rashi; Schindewolf, Craig; Lokugamage, Kumari G.; Scharton, Dionna; Plante, Jessica A.; Mirchandani, Divya; Widen, Steven G.; Narayanan, Krishna; Makino, Shinji; Ksiazek, Thomas G.; Plante, Kenneth S.; Weaver, Scott C.; Lindstrom, Stephen; Tong, Suxiang; Menachery, Vineet D.; Thornburg, Natalie J.
      Emerging Infectious Diseases (2020), 26 (6), 1266-1273CODEN: EIDIFA; ISSN:1080-6059. (Centers for Disease Control and Prevention)
      The etiol. agent of an outbreak of pneumonia in Wuhan, China, was identified as severe acute respiratory syndrome coronavirus 2 in Jan. 2020. A patient in the United States was given a diagnosis of infection with this virus by the state of Washington and the US Centers for Disease Control and Prevention on Jan. 20, 2020. We isolated virus from nasopharyngeal and oropharyngeal specimens from this patient and characterized the viral sequence, replication properties, and cell culture tropism. The virus replicates to high titer in Vero-CCL81 cells and Vero E6 cells in the absence of trypsin. We also deposited the virus into 2 virus repositories, making it broadly available to the public health and research communities. We hope that open access to this reagent will expedite development of medical countermeasures.
      >> More from SciFinder ®
      https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtlarurvN&md5=89075c420b0de7e286500c984a4e5a42
    17. 17
      Cyranoski, D. Profile of a killer: The complex biology powering the coronavirus pandemic. Nature 2020, 581, 22– 26,  DOI: 10.1038/d41586-020-01315-7
      17
      Profile of a killer: the complex biology powering the coronavirus pandemic
      Cyranoski, David
      Nature (London, United Kingdom) (2020), 581 (7806), 22-26CODEN: NATUAS; ISSN:0028-0836. (Nature Research)
      Scientists are piecing together how SARS-CoV-2 operates, where it came from and what it might do next - but pressing questions remain about the source of COVID-19.
      >> More from SciFinder ®
      https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXosV2jurc%253D&md5=826e66de35a020886c414db4dbdd0ed0
    18. 18
      Becerra-Flores, M.; Cardozo, T. SARS-CoV-2 viral spike G614 mutation exhibits higher case fatality rate. Int. J. Clin. Pract. 2020,  DOI: 10.1111/ijcp.13525
      There is no corresponding record for this reference.
    19. 19
      Merad, M.; Martin, J. C. Pathological inflammation in patients with COVID-19: A key role for monocytes and macrophages. Nat. Rev. Immunol. 2020, 20, 355– 362,  DOI: 10.1038/s41577-020-0331-4
      19
      Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages
      Merad, Miriam; Martin, Jerome C.
      Nature Reviews Immunology (2020), 20 (6), 355-362CODEN: NRIABX; ISSN:1474-1733. (Nature Research)
      A review. Abstr.: The COVID-19 pandemic caused by infection with SARS-CoV-2 has led to more than 200,000 deaths worldwide. Several studies have now established that the hyperinflammatory response induced by SARS-CoV-2 is a major cause of disease severity and death in infected patients. Macrophages are a population of innate immune cells that sense and respond to microbial threats by producing inflammatory mols. that eliminate pathogens and promote tissue repair. However, a dysregulated macrophage response can be damaging to the host, as is seen in the macrophage activation syndrome induced by severe infections, including in infections with the related virus SARS-CoV. Here we describe the potentially pathol. roles of macrophages during SARS-CoV-2 infection and discuss ongoing and prospective therapeutic strategies to modulate macrophage activation in patients with COVID-19.
      >> More from SciFinder ®
      https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXoslOqt7s%253D&md5=d38b037fed1fcc469e6c8caa23777fc7
    20. 20
      Thamphiwatana, S.; Angsantikul, P.; Escajadillo, T.; Zhang, Q. Z.; Olson, J.; Luk, B. T.; Zhang, S.; Fang, R. H.; Gao, W.; Nizet, V.; Zhang, L. Macrophage-like nanoparticles concurrently absorbing endotoxins and proinflammatory cytokines for sepsis management. Proc. Natl. Acad. Sci. U. S. A. 2017, 114, 11488– 11493,  DOI: 10.1073/pnas.1714267114
      20
      Macrophage-like nanoparticles concurrently absorbing endotoxins and proinflammatory cytokines for sepsis management
      Thamphiwatana, Soracha; Angsantikul, Pavimol; Escajadillo, Tamara; Zhang, Qiangzhe; Olson, Joshua; Luk, Brian T.; Zhang, Sophia; Fang, Ronnie H.; Gao, Weiwei; Nizet, Victor; Zhang, Liangfang
      Proceedings of the National Academy of Sciences of the United States of America (2017), 114 (43), 11488-11493CODEN: PNASA6; ISSN:0027-8424. (National Academy of Sciences)
      Sepsis, resulting from uncontrolled inflammatory responses to bacterial infections, continues to cause high morbidity and mortality worldwide. Currently, effective sepsis treatments are lacking in the clinic, and care remains primarily supportive. Here we report the development of macrophage biomimetic nanoparticles for the management of sepsis. The nanoparticles, made by wrapping polymeric cores with cell membrane derived from macrophages, possess an antigenic exterior the same as the source cells. By acting as macrophage decoys, these nanoparticles bind and neutralize endotoxins that would otherwise trigger immune activation. In addn., these macrophage-like nanoparticles sequester proinflammatory cytokines and inhibit their ability to potentiate the sepsis cascade. In a mouse Escherichia coli bacteremia model, treatment with macrophage mimicking nanoparticles, termed MΦ-NPs, reduced proinflammatory cytokine levels, inhibited bacterial dissemination, and ultimately conferred a significant survival advantage to infected mice. Employing MΦ-NPs as a biomimetic detoxification strategy shows promise for improving patient outcomes, potentially shifting the current paradigm of sepsis management.
      >> More from SciFinder ®
      https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1aisr7J&md5=7d85b146ca874333f82bed02c57bdabd

  • Supporting Information

    Supporting Information

    ARTICLE SECTIONS
    Jump To

    The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acs.nanolett.0c02278.

    • Materials and methods, Figure S1, and Table S1 (PDF)


    Terms & Conditions

    Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: http://pubs.acs.org/page/copyright/permissions.html.

PDF [ 3MB]

Pair your accounts.

Export articles to Mendeley

Get article recommendations from ACS based on references in your Mendeley library.

Pair your accounts.

Export articles to Mendeley

Get article recommendations from ACS based on references in your Mendeley library.

You’ve supercharged your research process with ACS and Mendeley!

STEP 1:
Click to create an ACS ID

Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

MENDELEY PAIRING EXPIRED
Your Mendeley pairing has expired. Please reconnect